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Pregnancy is an immunological paradox in which the semi-allogenic fetus is not rejected by the 
mother's immune system. Immunization against the Human platelet antigen (HPA)-1a antigen takes 
place in 1:1,000 pregnancies, as a break of this tolerance. The HPA-1a antigen is a platelet antigen, 
and platelets have naturally been the subject of focus regarding both the cause and the effect of 
HPA-1a alloimmunization. HPA-1a immunization in pregnancy has been seen as a cause of feto-
maternal transfer of platelets during pregnancy and at delivery and the consequences of 
thrombocytopenia have been seen as an effect of anti-HPA-1a antibodies. However, it is known that 
the HPA-1a antigen is not platelet specific and that the antigen is expressed also in fetal cells in the 
placenta and in fetal endothelium. Placental debris is shed into the maternal circulation due to 
placental turnover during pregnancy, so HPA-1a in the placenta is a potential source of antigen for 
alloimmunization. In addition, HPA-1a in both the placenta and in the endothelium of the fetus are 
potential places for the effect of anti-HPA-1a-antibodies. In recent years, there has been increasing 
focus on the potential differences in anti-HPA-1a antibodies against the 3 integrin itself and the β3 
integrin in complex with αV or αIIβ. The differences in specificities of anti-HPA-1a antibody 
antibodies made in HPA-1a negative women may reflect differences in antigen source. We show 
here that HPA-1a-specific T cells are activated by antigen associated with αVβ3 from trophoblast in 
the same way as antigen associated with IIb3 from platelets and that the HPA-1a antigen may be 
found in plasma of HPA-1a negative women pregnant with an HPA-1a positive fetus in the form of 
extracellular vesicles and that these vesicles may be of placental origin, suggesting that the source 
of antigen in HPA-1a immunization also may be placental extracellular vesicles. We also show that 
the anti-HPA-1a antibody 26.4 binds V3 integrin and affects adhesion and migration in a 
trophoblast cell line.  
The production of IgG anti-HPA-1a antibodies is dependent on a T cell response, which in turn is 
dependent on presentation of the antigen in a major histocompatibility complex (MHC), and the 
DRA/DBR3*0101 MHC class II molecule has been shown to present HPA-1a antigen to T cells. In 
addition, several other human leukocyte antigen (HLA) alleles have been suggested or shown to be 
associated with immunization, albeit in conflicting reports, and the close linkage between genes in 
the MHC complex makes it difficult to interpret results on single alleles. We aimed to more 
precisely define which alleles have a role in HPA-1a immunization and here find that the 
prevalence of HPA-1a immunization is higher when the DRB3*01:01 allele is associated with the 




There is a further need to more precisely select women most at risk of immunization for both follow 
up and treatment. Both the definition of risk factors in women and the knowledge of when and how 
the immunization occurs  which our work contributes to are important for follow up and to 




















Fetal and neonatal alloimmune thrombocytopenia: an overview 
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition in which fetal and 
neonatal platelets are depleted as a cause of anti-platelet antibodies made by the mother during 
pregnancy. The antibodies are produced because of differences in platelet antigen type between the 
mother and the fetus. Antibodies cross the placenta and destroy the baby's platelets, making the 
baby thrombocytopenic and at risk of bleeding. Common clinical signs are skin bleeding with 
petechias and ecchymosis. A more concerning and rarer clinical consequence is, however, 
intracranial haemorrhage (ICH), with possible severe sequela, including death.  
 
In 75–85% of the cases in Caucasians, FNAIT is caused by a difference in the human platelet 
antigen (HPA)-1 system between the mother and the fetus and the production of anti-HPA-1a 
antibodies by the mother (Figure 1) [1-3]. HPA-1a alloimmunization is the most common cause of 
both severe thrombocytopenia in fetuses and newborns and ICH in term newborns [4]. The HPA-1 
system is defined by a leucine/proline polymorphism in position 33 of the β3 integrin (GPIIIa) [5] 
which makes a heterodimer together with αIIb (GP IIb) on platelets, forming the fibrinogen 
receptor. The β3 integrin is, however, also found on other cell types – for example, together with 
αV, forming the vitronectin receptor [6, 7].  
 




Two percent of Norwegian pregnant women are HPA-1a negative and thereby at risk of being 
immunized during pregnancy with an HPA-1a positive fetus [8]. About 10 % of HPA-1a negative 
women develop anti-HPA-1a antibodies [8-11], and the making of antibodies does not necessary 
lead to thrombocytopenia in the fetus. FNAIT caused by HPA-1a antibodies is found in 1:1,000-
1,200 newborns [8, 10]. ICH is reported to occur in some FNAIT cases due to anti-HPA 1a 
antibodies [8, 9, 12], and most of those cases already occur in utero [13, 14]. HPA-1a immunization 
is also associated with reduced birth weight in baby boys [15]. There is currently no screening for 
the condition, and the condition is underdiagnosed in routine clinical practice [16]. In addition, 
there is currently neither specific treatment nor prophylaxis for the condition. The ongoing 
treatments available are general and differ between countries. Without any treatment, the 
thrombocytopenia resolves within some weeks after birth [17]. 
 
Immunization is clearly associated with the HLA allele DRB3*01:01 [8, 10, 18]. The molecular 
mechanism of this association is now also well known: the HPA-1a peptide fits well into the 
peptide-binding groove of HLA-DRA/DRB3*0101 and is presented to HPA-1a specific T cells [19-
21]. Also, other HLA alleles are proposed to be associated with immunization, albeit without 
explanation beyond a statistical allele association.  
In this thesis, I will argue that, despite recent advances, our understanding of the pathogenesis of 
FNAIT remains limited, and there are several missing links.  
 
The making of the placenta and the role of 3 integrin 
The haemochorial placenta is formed when fetal-derived cells (trophoblast) invade a modified layer 
of the maternal uterus, the decidua, in early pregnancy (Figure 2) [22]. Placenta is a temporary but 
highly specialized organ and is responsible for the normal, or physiological, exchange between the 
developing fetus and the mother during pregnancy. The villous trophoblasts line the villi in the 
placenta with the inner layer of cytotrophoblasts (CTB) and the outer layer of syncytiotrophoblasts 
(ST). Placenta represents the closest proximity of the maternal and fetal circulations [23], and at 
term, the ST line an area of about 11–13 m2 in a normal placenta [24]. A subset of cytotrophoblasts 
(CT) in anchoring villi aggregate into cell columns that attach to the uterine wall and invade the 
uterine wall (extravillous cytotrophoblast, EVT) and its blood vessels (endovascular 
cytotrophoblast) as far as the first third of the myometrium [25]. Endovascular trophoblast cells 




arteries are maternal arteries that supply the placenta with blood, and remodelling of these arteries is 
necessary for an adequate blood supply to the placenta. The replacement of SMCs makes a low–
resistance system allowing continued blood flow to the placenta and the fetus.  
 
 
Figure 2. Graphic presentation of the feto-maternal interface. Mφ/D = macrophage/dendritic cells; 
DC = dendritic cells. The figure is reprinted with permission from Leòn-Juàrez et al., 2017 [26], 
doi: 10.1093/femspd/ftx093.  
 
Bowen and Hunt (2000) [27] present a review with focus on integrins and their presence and 
function from fertilization, at implantation, and during placental development. The integrin most of 
interest to describe here is one involving the 3 integrin: the vitronectin (V3) receptor. Human 
oocytes express 3 integrin, and in the very earliest phase of implantation, V3 is released from 




attachment between sperm and egg and sperm aggregation. An anti-V3 antibody with blocking 
characteristics, however, does not affect sperm-egg binding [27]. V3 is also one of the receptors 
considered to be particularly important during the initial process of implantation [27] [28]. Human 
uterine epithelium express V3, and the expression rises with the rise in progesterone during the 
window of implantation [27]. There is naturally little knowledge about the in vivo integrin 
expression by human trophoblast cells at the time of implantation. Examination of mouse 
trophectoderm, however, showed that it expresses V3 during the initial stages of apposition and 
adhesion [27]. Exposure of hormones and cytokines during pregnancy may influence both the 
expression and activation of the V3 integrin. The activation of V3 integrin was, for example, 
reduced in response to IFN in endothelial cells, and oestrogen both with and without progesterone 
downregulated the integrin in an endometrial adenocarcinoma cell line [29].  
Cells at the terminal end of the trophoblastic column express the V3 integrin, which may 
facilitate invasion and development of the placenta. Primary CTs that mediate invasion through 
Matrigel and collagen need the V3 and 11 to promote migration [30], and V3 and -1 
integrins also mediate adhesion of human CT to endothelial cells in vitro, suggesting that these cells 
may have similar effects on endovascular trophoblast adhesion and migration within the uterine 
arteries in vivo [30]. V3 integrin is even enhanced on CT that has invaded the uterine wall and 
maternal vasculature [25].  
Other indications of the importance of V3 in placentation are that lack of expression of 3 in the 
human epithelium has been associated with unexplained infertility and that in preeclampsia the 
upregulated expression of integrin subunits 11 or V3 in cytotrophoblasts does not occur. 
Whether this is a cause or an effect of preeclampsia, however, is not known [27]. 
 
Alloimmune responses 
Both the fetus and the placenta may be described as allografts, and because the fetus may be an 
allograft to the mother, pregnancy could be seen as a state of transplantation. Adaptive immune 
responses are the most important threat to the success of transplantation of a grafted tissue or organ 
between individuals. Transplants between allogeneic individuals are rejected because of T cell 
responses in the recipient against the polymorphic MHC molecules on the transplant, where 
differences in these major alloantigens can cause acute rejection due to direct recognition by host T 
cells. However, rejection may also appear in MHC-identical grafts as a cause of differences in other 




barrier to transplantation when they are presented together with specific class I and class II MHC 
molecules. Such antigens may cause rejection of the allograft, both acute and chronic, as well as 
graft-versus-host disease (GVHD) [31].  
 
HPA-1a immunization is an allo-response, and “immunization” refers to the production of anti-
HPA-1a antibodies. The potential harmful effect the condition has on the fetus is caused by the 
antibodies. However, the production of these antibodies in HPA-1a negative women is also 
dependent on a T helper cell response to the same antigen, which is further dependent on the 
presentation of the antigen in a specific MHC-complex. This is a key event in the immune response 
that results in IgG production.  
 
Another well-known situation in which alloimmune responses may arise, which also resembles the 
situation in HPA-1a alloimmunization, is through transfusion of red blood cells, which may cause 
alloimmune responses against antigens in the AB0 or Rhesus (Rh) system. The human Rh locus 
consists of two related genes, encoding the D, Cc, and Ee blood group antigens. D is the major 
cause of Rh incompatibility, and it is estimated that 15–17% of Caucasians do not express the D 
antigen and are hence Rh negative [32] and at risk of immunization when exposed to the D antigen. 
The D antigen is strongly immunogenic [32]. Despite that, however, the incidence of primary RhD 
immunization also depends on the dose of RhD-positive red cells. Fifteen percent of women at risk 
will show a primary immune response against the D antigen after the intravenous delivery of 1 mL 
RhD-positive red cells. A secondary immune response, however, may occur after exposure of as 
little as 0.03 mL RhD positive red cells [32]. As a consequence, the disease only develops when the 
RhD negative mother has had a significant transplacental haemorrhage (TPH). The average TPH 
occurring at delivery is, however, less than 1 mL of whole blood [32]. During pregnancy, small 
fetal bleeds may lead to sensitization, followed by a larger volume, leading to immunization, at 
delivery [32-34]. An antibody-based prophylaxis against Rhesus immunization has been available 
for several years (1965–1970). Early studies of the vaccine effect the AMIS effect) more than 50 
years before the description of the anti-D effect found that the antigen-specific IgG antibody can 
suppress the antibody response to particulate antigens. Despite both the overall use and obvious 
effect of this vaccine – the immunomodulatory effect it induces is not well described. However, 






Alloantigens are antigens presented only in some individuals of a species that are capable of 
inducing the production of alloantibodies by individuals who lack the antigen. The polymorphic 
MHC antigens responsible for transplant rejection, encoded within the MHC complex, have already 
been mentioned as such alloantigens. Other possible alloantigens are the human platelet antigens 
and other mHAgs. T cells specific for different fetal mHAgs [31, 36] can be found in multiparous 
women. 
 
Human platelet antigens 
Human “platelet alloantigens are defined by alloantibodies directed against genetically determined 
molecular variations of proteins or carbohydrates on the platelet membrane” [37]. The human 
platelet alloantigens can be divided into two groups: type I platelet alloantigens that consist of 
antigen systems also found on other cell and tissue types – for example, MHC molecules – and type 
II platelet alloantigens that consist of platelet specific antigens [37]. Platelet-specific alloantigens 
are defined as all protein alloantigens expressed on the platelet membrane except those encoded by 
genes of the MHC [38]. However, many previously considered platelet specific antigens are also 
detected on other cells and tissues and are not platelet specific. 
 
The human platelet antigen nomenclature system was adapted in 1990 by the ISBT platelet working 
party [38] and aims to categorize human platelet specific protein alloantigens (HPAs): HPAs are 
formed due to genetic cell variants of glycoproteins on the platelet surface [39]. The antigen system 
is numbered in order of discovery with the higher frequency antigen designated “a” and the lower 
frequency antigen designated “b” [40]. In almost all of the serologically defined antigens, the 
difference between high and low frequency alleles is defined by a single amino acid substitution 
[37]. Twelve antigens are clustered into six bi-allelic groups [39]. For the six bi-allelic HPA 
systems, SNP typing on large numbers of DNA samples has also provided information on allele 
frequencies, with significant differences occurring between populations.  
To date, a total of 35 HPA antigens have been designated in 29 systems (HPA 1-29) [40-47], 
detected on six different glycoproteins (GPs): ITGB3, ITGA2B, ITGA2, GPIBA, GP1BB, and 
CD109 (https://www.versiti.org/medical-professionals/precision-medicine-expertise/platelet-
antigen-database#hpa-database) that may cause alloimmune complications. For the current list, see 




IIb3 integrin (fibrinogen receptor) [48]. Alloimmunization in pregnancy against recognized but 
low-frequency HPAs, not resolved by standard typing, accounts for only a few FNAIT cases [39].  
 
Placenta antigens 
mHAgs are also expressed in syncytiotrophoblast and in trophoblast debris shed from the placenta 
[49]. Hence, the placenta may be a source of mHAgs exposed to the mother during pregnancy.  
Integrin β3 is, in addition to being part of the fibrinogen receptor (αIIbβ3), also part of the 
vitronectin receptor (αVβ3) found on different cells types, including trophoblast cells [7, 30, 50, 
51]. In the placenta of week 10–18, the 3 integrin is found in distal columns CT, interstitial 
placental bed, endovascular placental bed, and the maternal endothelium [25]. In sections of second 
trimester (18–22 weeks) placenta, V3 was weakly expressed or not detected by antibody staining 
on villous CT or in the initial layers of cell columns. However, strong staining for V3 was 
detected on CT within the uterine wall and in uterine vasculature. In addition, 3 integrin has been 
detected on placental syncytiotrophoblast microvilli [50-52]. 
 
Immunology of the placenta 
Pregnancy is an immunological paradox in which the semi-allogenic transplant – the fetus – is not 
rejected by the immune system of the mother. The mother tolerates the fetus and lets it develop for 
9 months despite the fact that she is naïve to its paternally derived antigens, is not 
immunosuppressed and is still likely capable of making a response to invading pathogens. 
Medawar, in 1953, postulated three general mechanisms which make the uterus an immune-
privileged site during pregnancy: the induction of tolerance in the mother for paternal derived 
antigens, the construction of an anatomical and physiological barrier between the mother and the 
fetus, and a reduced expression of alloantigens by fetal cells [53]. However, these three mechanisms 
have later been challenged. 
The anatomical arrangement of the haemochorial placenta gives many possibilities for exposure of 
maternal blood and immune cells to trophoblast cells, trophoblast debris and fetal cells, and their 
antigens [54]. As described, the area of ST in a normal term placenta in contact with maternal blood 
is large [55], and migration of extracellular trophoblast proceeds deep into the myometrium of the 




leucocytes through both extravillous trophoblast in contact with maternal tissue and blood and 
villous ST in contact with maternal blood.  
 
The expression of paternal MHC on the surface of trophoblast cells could, in theory, predispose the 
placenta to serve as a target of an anti-fetal allo-response. However, both ST and EVT cells lack 
HLA class II [56] and classical HLA class I A and B on the cell surface [57, 58] and are thereby in 
a way protected against an immune response against foreign HLA polymorphisms. EVTs do still 
express the class I protein HLA-C, which in principle is polymorphic. HLA-C in the placenta, 
however, has reduced polymorphism compared to other class I molecules and is also only weakly 
expressed on EVTs [59].  
 
The lack of a noticeable immune response to MHC incompatibility between mother and fetus, 
described above, could be explained by the lack of MHC class II expression and the low MHC class 
I expression in areas accessed by the maternal blood. Despite this, however, pregnancy can elicit 
lymphocyte responses to both major and minor histocompatibility antigens from the fetus [54]. 
HLA class I has been shown to be expressed on cells in the villous stroma, and Hofbauer cells, 
which are placental villous macrophages of fetal origin, also exhibit MHC class II proteins [54]. 
Furthermore, the lack of class II on trophoblast cells is challenged by Ranella et al. (2005) who 
report expression of both HLA-DR and HLA-DO intracellularly in trophoblasts [60]. In sum, there 
are several potential alloantigens available for the mother’s immune system to react to: class I and II 
from fetus and villous stromal cells; HLA-C from EVTs; or minor antigens from trophoblast, 
villous stromal cells, or fetal cells that travers the placenta during pregnancy (microchimerism) 
[54].  “There is no longer doubt that maternal T and B cells are aware of fetal antigens, that they 
respond to the presence of the fetus, and that under normal circumstances they are tolerant to these 
antigens” [61]. The question, then, is no longer whether or not the mother is “aware” [62] of fetal 
allo-antigens, but what the cellular and molecular events leading to acceptance of the fetus are, 
regardless of their expression. In that respect, several mechanisms have been suggested to be of 
importance for the acceptance of the fetus, some of which are briefly explained in the following 
paragraphs.  
 
Instead of the classical HLA class I, EVTs express HLA-G. For HLA-G, there are 50 alleles (per 




isoforms exist [63]. HLA-G is expressed mainly in membrane-bound form at the feto-maternal 
interface, in a few adult tissues, and in different cells such as activated monocytes and erythroid and 
endothelial precursors [64]. Soluble HLA-G is found in body fluids, such as plasma [65]. HLA-G 
binds the inhibitory receptors LILRB1, LILRB2, and KIR2b14, which are differentially expressed 
by immune cells. Binding of these receptors may have an effect both on effector- and antigen-
presenting cells: inducing apoptosis of activated CD8 positive T cells, modulating the activity of 
NK cells and dendritic cells, blocking alloantigen-specific cytotoxic T cell response, and inducing 
expansion of regulatory T cell populations [63].  
 
The different maternal leukocytes in the decidua are also under the influence of fetal cells. Briefly, 
these influences could generally be called tolerance-promoting. Non-classical HLA class I on EVTs 
act as modulators of Tc, uterine NK cells (uNKc), macrophages, and dendritic cells (DCs) [66], and 
both trophoblasts and maternal macrophages in decidua produce different potent immunoregulatory 
molecules [66-68]. The phenotype of uNK cells in the decidua also differ from those in peripheral 
blood. These cells express killer inhibitory receptors (KIRs) that are specific for HLA class I on 
EVTs. In addition, CD8 effector T cells in decidua are non-functional since the production of 
cytotoxic molecules is downregulated. This hinders cytolysis of EVTs by CD8 T cells [69].  
 
The activation state of a DC is decisive for the outcome of the meeting between a DC and a naïve T 
cell [54], and anti-inflammatory factors like IL-10, progesterone, human chorionic gonadotropin 
(hCG), and oestradiol may induce tolerogenic dendritic cells [70]. T regs also accumulate in the 
decidua, where they are attracted by hCG, in contrast to the decrease in T regs in maternal 
circulation [69]. 
 
Reports conflict regarding the presence of lymphatic vessels in the endometrium and decidua [71]. 
Red-Horse et al. showed in 2006 that the human non-pregnant endometrium does not contain 
lymphatic vessels [72, 73], while pregnancy induces lymph angiogenesis in decidual parts of uterus, 
and trophoblast cells are found in close proximity to these vessels [72]. Volchek et al. (2010), 
however, showed that lymphatic vessels were abundant in non-decidualized hypersecretory 
endometrium during gestation, while the decidua was nearly always free of lymphatics. In 




stromal cells [71]. Among the explanations of the opposite findings in these two publications is the 
wide definition of the decidua by Red-Horse et al.  
 
During pregnancy, the fetus is protected against disease by maternal antibodies. IgG antibodies of 
high concentration in the maternal circulation are transported to the fetus via the placenta [74]. The 
antibodies are endocytosed by the syncytiotrophoblast, bind the human neonatal Fc receptor 
(FcRn) in the acidic environment in the endosome and are further transported to the fetal side. The 
transport of antibodies happens predominantly in the third trimester and is important for protection 
of the fetus and newborn child until it makes a sufficient number of antibodies by itself: maternal-
fetal transport of IgG via the FcRn in the syncytiotrophoblast provides passive immunity to the 
fetus. IgA and IgM are not transferred from the mother to the fetus because specific receptors in the 
placenta for these immunoglobulins do not exist [74]. 
 
Platelets and their expression of integrins in fetuses and newborns 
Platelets are the primary effector of haemostasis, in addition to having a potentially wide range of 
other physiological and pathological effects [75]. The normal platelet count in adults is 150–450 
x109/L. By between 18 and 21 weeks of gestation, platelet values in fetuses are reported to be 234  
57 [76], resembling the adult values for platelets. Israels et al. 2003 [77] also found that platelet 
counts in full term newborns are not different from adult values, and that mean platelet numbers for 
infants between 18 and 30 weeks of gestation are 250 [78, 79]. In even younger fetuses, between 10 
and 17 weeks of gestation, platelet counts are reported to be somewhat lower: 159  34 [76]. 
 
There is limited knowledge about the function of fetal platelets and the regulation of platelets within 
the developing fetus in vivo [80], but fetal and neonatal platelets have in general been characterized 
as hyporeactive. Studies of platelet aggregation have shown that the aggregation of neonatal 
platelets is lower than with adult platelets [81, 82]. In a recent review, however, Margraf et al. 
(2019) [80], reported that bleeding time in the newborn is similar to, or shorter than, bleeding time 
in adults.  
 
Integrins, receptors for adhesive proteins, including IIbß3, are present on fetal and cord blood 




these receptors on both neonatal (term) and fetal platelets is similar to the number on adult platelets 
[85-87]. Gruel et al. (1986) found that IIb3 appeared to be normally expressed on fetal platelets 
as early as 18 weeks of gestational age and that HPA-1 is expressed on platelets at the same 
frequency and quantity in fetuses between 18 and 26 weeks of gestation as in adults [87]. 
 
However, Margraf et al. (2019) note that IIb3 is reduced in neonatal versus adult platelets [80]. 
Sitaru et al. (2005) [88] also analysed the expression of platelet glycoproteins and platelet activation 
markers both in cord blood and in peripheral venous blood through whole blood flow and found a 
lower level of IIb3 expression on platelets from peripheral blood in term newborns as well as 
preterm infants compared to adults. Simak et al. (1999) [86] also found a significantly lower 
expression of IIb3 in the membrane of resting neonatal platelets compared with adult platelets by 
examining full blood in flow cytometry. Thus, it is well documented that fetuses have relatively 
high concentration of platelets, also carrying 3 integrin already from early stages of pregnancy, 






Human leucocyte antigens (HLA) and HLA haplotypes 
The MHC complex is located on chromosome 6 and contains several genes located close together 
(Figure 6). The complex consists of three basic groups of genes: class I, class II, and class III. Class 
I encodes for HLA-A, -B, and –C molecules, class II encodes for HLA-DR and –DQ-molecules, 
and class III encodes for molecules primarily involved in inflammation.  
 
 
Figure 3. The MHC complex of chromosome 6. Commons.wikimedia.org 
 
HLA class II molecules are proteins with one alpha- and one beta-chain coded for in the MHC class 
II region. Several allelic variants of DRB- and DQ alleles as well as of HLA-A, -B, and –C alleles 
give rise to the wide polymorphism in HLA molecules. An HLA-DQ molecule, for example, 
consists of an alpha chain encoded for in DQA, and one beta chain encoded for in DQB. This 
applies also to the DR molecules. However, for DR molecules the beta chain, in addition to being 
encoded for in DRB1, may also be encoded for by allelic variants of DRB3, 4, or 5, and most 
individuals carry such an extra DRB locus [89].  
 
 
HLA-associations in HPA-1a alloimmunization 
HPA-1a alloimmunization is strongly associated with HLA-DRB3*01:01 [90-92]: over 90% of 




data). In retrospective studies of HPA-1a alloimmunization, all or almost all immunized women 
were DRB3*01:01 positive [10, 93]. The crystal structure of HLA-DRB3*0101 was resolved in 
2007, with a modified HPA-1a peptide in the peptide-binding groove [21]. Parry et al. (2007), 
described structural studies of the DRA/DRB3*0101 molecule in complex with an N-terminal 
fibrinogen glycoprotein peptide which contains a Leu/Pro dimorphism [21]. Further, Ahlen et al. 
(2009) showed that isolated HPA-1a specific T cells from immunized women were 
DRA/DRB3*0101 restricted [94]. HPA-1a derived peptide binds the DRA/DRB3*0101 molecule, 
where the allogeneic residue L33 functions as an anchor residue [19]. Rayment et al. (2009) 
characterized T cell clones derived from several FNAIT mothers, confirmed that they respond to 
HPA-1a positive platelets, and defined their restricting class II molecule and epitope “core” [95].  
 
The risk of HPA-1a immunization postpartum in DRB3*01:01 positive women is 12.7%, compared 
to 0.5% in DRB3*01:01 negative women [96]. Kjeldsen-Kragh et al. (2019) also demonstrated that 
the DRB3*01:01 allele has a significant dose-dependent effect on maternal anti-HPA-1a levels, 
while the opposite trend is seen for neonatal platelet counts [97]. Wienzek-Lischka et al. (2017) did 
not, however, find any association between platelet count or ICH in the neonate and DRB3*01:01 
heterozygosity or homozygosity in the mother [91]. In summary, there is a clear HLA-
DRB3*01:01-association in HPA-1a immunized women, there is a dose-dependent relationship 
with anti-HPA-1a alloantibody formation, and the association has a molecular explanation.  
 
Làbbe et al. showed in 1992 that another HLA allele, HLA-DQB1*02:01, is also strongly associated 
with HPA-1a alloimmunization [18]. DQB1*02:01 was found in 94% of immunized women 
compared to 40% in the control population, and the association of DQB1*02:01 with HPA-1a 
immunization is one of the strongest found to date [18]. In addition, the HLA-DQA1*05:01 allele 
was found in 86% of the immunized women. However, there are no reports of a function of 
DQA1*05/DQB1*0201 in relation to FNAIT. Neither are there any reports of FNAIT-associated T 
cell responses restricted by DQ2 molecules. The explanation for this association remains unknown.  
 
A third HLA-allele, DRB4*01:01, has been proposed to have importance in the immunization 
against HPA-1a [98]. Loewenthal et al. (2013) found that 61% of HPA-1a immunized women in 
their study group carried this allele, compared to only 38% in the control group (women giving 




this case also including DRB4*01:03) was found more frequently in FNAIT cases compared to 
controls both with and without the presence of the DRB3*01:01 allele [98]. By modelling the 
structure of DRA/DRB4*0101 and comparing it to the structure of DRA/DRB3*0101, the study 
concluded that DRA/DRB4*0101 also forms a binding cavity that might prefer binding L33 over 
P33, despite the lower avidity of the epitope compared to DRA/DRB3*0101, and that the 
DRB4*01:01 allele thereby might be a contributor in the development of FNAIT, at least in 
combination with DRB3*01:01 [98]. However, no difference in platelet number or in the response 
to treatment between having two or one associated alleles was found [98].  
In contrast to the overrepresentation of DRB4*01:01 in the above-mentioned study, Labbe et al. 
(1990) found a DRB4*01:01 frequency of 41.7% in immunized women, compared to 70% in non-
immunized women [18]. Wienzek-Lischka et al. (2017) also found that the frequency of 
DRB4*01:01P was lower in FNAIT cases compared to 100 healthy controls [91]. In addition, they 
did not find any association between the platelet count or ICH of the neonate and the absence or 




HLA haplotypes are clusters of HLA gene alleles that are inherited together because of their close 
linkage on chromosome 6 [99]. An HLA-DR-DQ haplotype consist of a combination of specific 
allelic variants of DRB1, DQA1, and DQB1.  
High-resolution typing of HLA-DR-DQ haplotypes in European Americans (2003) established new 
HLA haplotype frequency reference standards and established frequencies of the class II loci 
DRB1, DQA1, and DQB1 [100]. A total of 75 distinct DRB1-DQA1-DQB1 haplotypes were 
identified in the sample, and most of the common haplotypes were already known from previous 
studies on European populations [100]. Frequency distribution of the 75 haplotypes showed that as 
many as 59 haplotypes occurred at frequencies of less than 1%, including a total of 21 haplotypes 
that occurred only once and a further 6 that were seen only twice. Only 16 haplotypes occurred at a 
frequency >1% [100]. High resolution HLA haplotype frequencies derived from the US donor 
registry showed that there were 33 common DRB1 alleles, which accounted for 99.5% of all the 
DRB1 alleles; 15 common DQB1 alleles, which accounted for 99.9% of all DQB1 alleles; and 8 





The HLA-DRB3*01:01 allele is associated with DRB1*03, DRB1*11, DRB1*12, DRB1*13, and 
DRB1*14 alleles in different HLA-DR-DQ haplotypes [102, 103]. Among the 100 most common 
haplotypes from the US donor registry, the DRB3*01:01 associated DRB1-alleles DRB1*03:01 
(0,06526), DRB1*03:02 (0,00010), DRB1*14:06 (0,00003), DRB1*03:01 (0,00864), DRB1*14:02 
(0,00001), DRB1*14:02 (0,00001), and DRB1*13:01 (0,00035) are represented [101].  
 
DRB1*14 positive individuals from different US population groups with a single DRB3-associated 
DRB1 allele were selected for identification of the DRB3 association (that is, not DRB1*03, 11, 12, 
or 13) [104]. Of these, in the Caucasian population, 90% were DRB1*14:01 positive, and only 2% 
were DRB1*14:02 positive. The DRB1*14:02 allele was also associated with DRB3*01:01 [104] 
and comes with DQB1*03:01 in the DR14-DQ3 haplotype, at low frequency [101]. Hence, the 
DRB3*01:01-associated DR14-DQ3 haplotype is very rare in Caucasians.  
 
For DRB1*03, in 161 positive individuals from each of five US population groups, only 6 of 21 
known alleles were detected, and Caucasians were found to be the least diversified, in whom only 
DRB1*03:011 was observed [102]. Among only the Caucasoid population 23.4% were DRB1*03 
positive, and the allele came in the following combinations: DRB1*03:011 + DRB3*01:01 in 
83.1%, DRB1*03:01 + DRB3*02:02 in 16.2%, and DRB1*03:011 + DRB3*03:03 in 0.8% [102].  
 
For DRB1*13 alleles the frequencies in Caucasians were found to be: 48.6% for DRB1*13:01, 
40.0% for DRB1*13:02, 8.6% for DRB1*13:03, and 1.7% for DRB1*13:05. The most common 
allele, DRB1*13:01, came in the following combinations: DRB1*13:01-DRB3*01:01: 63%, and 
DRB1*13:01-DRB3*02:02: 37% (N = 51). The other DRB1*13 alleles came in the following 
combinations: DRB1*13:02-DRB3*03:01: 100% (N = 37), DRB1*1303-DRB3*01:01: 91% (N = 
11), and DRB1*13:03-DRB3*02:02: 9% (N = 11) [103].  
  
HLA haplotypes in HPA-1a alloimmunization 
The most important from the above section is that HLA alleles do not exist alone. One of the 
DRB3*01:01 associated haplotypes is the DR3-DQ2 which also consist of HLA-DQB1*02:01, the 
other allele known to be associated with HPA-1a alloimmunization [18]. As already described, 




(2017) found that both these haplotypes have a similar effect on the case-control status [91]. 
DRB1*03-DRB3*01:01 is, however, overrepresented among HPA-1a immunized women compared 
to the DRB1*13-DRB3*01:01 haplotype [91]. The other DR-DQ haplotype containing DQ2 is the 
DR7-DQ2 haplotype, and DRB4*01 is again known to be associated with DR7-DQ2 [101].  
 
HLA haplotypes in the Norwegian population: 
When it comes to the Norwegian population, Spurkland et al. (1992) 30 years ago defined 24 
different HLA-DR-DQ haplotypes considered as common haplotypes in the Norwegian population, 
with frequency ≥ 1% in the population [105]. More recently, Lande et al. (2018), identified 4779 
NBMDR (Norwegian Bone Marrow Donor Registry) individuals recruited from Norwegian blood 
banks and genotyped for the loci HLA-A, -C, -B, -DRA, -DQB1, and -DPB1. The registry does not 
contain information regarding ethnicity [106]. The frequencies of different DR-DQ haplotypes of 
specific interest in this thesis were as follows: DR3-DQ2: 13.58%, DR7-DQ2: 5.8%, DR14-DQ5: 
2.55% (14:01-05:01), DR13-DQ6: 13.57% (13:01-06:03: 7.67%, 13:02-06:04: 5.11%, 13:02-06:09: 
0.61%), and DR14-DQ3: 0.16% (14:02-03:01) [106]. Some of the known DRB3*01:01 associated 
haplotypes are found rarely or not at all in the Norwegian population [105-107]. 
 
Epidemiological studies indicate different rates of immune related diseases in Sami compared with 
non-Sami Norwegian population [107]. Genomic data for HLA class I and II loci in Norwegian 
Sami show that several alleles and haplotypes differ from the Norwegian population. For alleles and 
haplotypes of specific interest here, the DRB1*03 allele was found at a frequency of 0.06 in Sami 
versus 0.124 in non-Sami, the DQB1*02 allele was found at a frequency of 0.063 in Sami versus 
0.179 in non-Sami, the DR3-DQ2 haplotype at a frequency of 0.06 in Sami versus 0.13 in non-
Sami, and the DR7-DQ2 haplotype at a frequency of 0 in Sami versus 0.05 in non-Sami [107].  
 
Conserved extended haplotypes/Ancestral haplotypes 
The DR3-DQ2 haplotype is also part of the conserved extended haplotype or ancestral haplotype 
(AH) 8.1 [99]. The term “ancestral” suggests that this is “conserved, population-specific haplotypes 
of larger continuous DNA sequences derived with little change from an ancestor of all individuals 
now carrying all or part of the haplotype” [99]. The haplotypes are built up from genotypes of four 
major blocks: HLA (w-N, TNF cluster, complement gene cluster and HLA-DQ-DR, and the AH 




constituents in the four major blocks are HLA-B8, TNF, mono-S-RCCX, and HLA-DQ2-DR3 
genotypes [108]. The existence of antigen non-specific control of immune response related to this 
AH has been demonstrated in mice. Also, in humans, a similar pattern has been suggested to be 
represented by the HLA-B8, DR3 haplotype, and the 8.1 AH is unique in its association with a 
number of immune pathological diseases [99] and cancer [109].  
 
Several polymorphic areas are documented within the TNF gene cluster. Polymorphism in the TNF 
promoter region has been observed to result in differences in the rate of gene transcription, and in 
the rate of protein production. Some of the polymorphisms are carried by the 8.1 AH [99]. There 
are, for example, reports of higher systemic levels of TNFα in healthy individuals with this 
haplotype [110]. However, the direct influence of AH 8.1 on TNFα-level is debated [110]. The 
biological functions of the TNF is also varied and complex. In the local acute situation, the 
production of TNF alpha is beneficial, while systemic or protracted exposure to TNF may be 
harmful [110].  
 
Fetal-maternal microchimerism and extracellular vesicles in pregnancy 
“Microchimerism refers to a small number of cells or DNA harboured by one individual that 
originated in a genetically different individual” [111]. During the course of a normal pregnancy, 
trafficking of cells occurs trans-placentally from the fetus to the mother and in the opposite 
direction. Both intact cells and DNA of fetal origin have been detected in maternal circulation [112, 
113]. By the second trimester, from 1 to 5 fetal cells/mL are found in maternal venous blood [40]. 
And trophoblasts are probably the major contribution of both fetal cells and DNA detected in 
maternal blood.  
 
The extracellular space of multicellular organisms contains a large number of membrane-limited 
vesicles called extracellular vesicles, microparticles, microvesicles, extracellular particles, and so 
on. Extracellular vesicles (EVs) are defined in different ways by size and by their origin. Gyorgy et 
al. [114] include exosomes, activation- or apoptosis-induced microvesicles or microparticles (MPs), 
and apoptotic bodies in the group of EVs. EVs also include other vesicular structures such as large 




Exosomes are vesicles of 50–100 nm in diameter generated by exocytosis of multivesicular bodies, 
while microvesicles are larger extracellular membrane vesicles of 100–1,000 nm in diameter 
formed by the release of budding/ blebbing of the plasma membrane of cells [114, 115]. The 
vesicles retain proteins from the cell of origin, along with cytosolic contents. Apoptotic bodies are 
made by the release from blebs of cells undergoing last stage of apoptosis and range from 1–5 μm 




Figure 4. Extracellular vesicles shed from the placenta.  
Reused from Tannetta, D. et al., Extracellular vesicles and reproduction–promotion of successful 
pregnancy. Cell Mol Immunol 11, 548–563 (2014). https://doi.org/10.1038/cmi.2014.42 
 
 
Formation of EVs has been observed in different kinds of cell types including endothelial cells, 
platelets, leukocytes, smooth muscle cells [116], erythrocytes [117], cancer cells [118], and 
trophoblast cells [119]. They are released from cells under stress and several stimuli may lead to or 
inhibit the formation of microvesicles. A database of the proteomes of EVs has recently been 





The placenta produces a wide variety of extracellular vesicles (Figure 4) [120]. The largest vesicles 
consist of syncytial nuclear aggregates. Those vesicles were already reported in 1893, when found 
trapped in cadaver lungs of pregnant women. Syncytial aggregates range from 20 µm up to 100 µm 
in size, contain hundreds of nuclei [121], and are found in maternal peripheral blood of pregnant 
women as early as 6 weeks of gestation [122]. The MVs are drained via the uterine vein into the 
maternal circulation. Lok et al. (2008) found that placenta-derived MVs ranged from 1.5 to 3% of 
the total number of microparticles isolated from maternal blood [123]. Microvesicles arise from 
budding of the plasma membrane [115] and therefore contain surface proteins from the cells that 
they are derived from. Placental microvesicles may arise from ST, villous CTs exposed to the 
maternal blood following denudation, and from EVTs [120]. One third of STs have blebs on their 
surface, suggested to be a source of trophoblast microvesicles [124]. The amount of MVs in 
maternal plasma has been reported to increase along with increasing gestation, and to reach the 
highest level at 36 weeks of gestation [123, 125]. Exosomes are also shed in large quantities from 
the ST in normal pregnancies, and the number of shed exosomes also increases with increasing 
gestational age [126].  
  
EVs also carry immunomodulatory proteins, by example HLA-G5 and FasL, that may contribute to 
apoptosis or reduced activity of T cells during pregnancy [127-130]. In addition, Syncytin-1 is 
expressed on EVs from placenta, which reduces the secretion of proinflammatory TNFα and IFNγ 
from leukocytes [131].  
 
Anti-HPA 1a antibodies 
Anti-HPA-1a antibodies are heterogeneous with respect of specificity of binding to 3 integrin. 
Hence, binding sites for these antibodies will differ between and within individuals, which will 
further influence the effect of the antibodies. Some anti-HPA-1a antibodies bind only to the β3 
chain, while others recognize complex epitopes formed by αIIb and β3 [132-134]. Antibodies 
against the latter will affect platelets, while antibodies which bind the 3 chain will potentially 
affect all cells with combinations of heterodimers, including the 3 integrin. Bayat et al. (2019) 
demonstrated that HPA-1a antibody subtypes currently used as standards for antibody testing also 
differ with regards to binding specificity [135], where “AP3” binds the 3 subunit independently of 




addition, a recent study by Santoso et al. (2016) demonstrates that anti-HPA-1a antibodies only 
reacting with the V3 complex were present in serum from mothers of ICH positive but not ICH 
negative FNAIT cases [136]. The binding of these antibodies to endothelial cells was further shown 
to reduce adhesion of the endothelial to vitronectin, lead to cell anoikis, and to interfere with 
angiogenesis [136]. Yougbare et al. (2015) also demonstrated in mice that anti-3 antibodies 
produced in mice may induce ICH in pups by impairing angiogenesis rather than by 
thrombocytopenia [137].  
 
The natural history of HPA-1a alloimmunization 
A large prospective screening study conducted in Norway, consisting of about 100,000 pregnant 
women, showed 2.1% HPA-1a negative women in the population [8], which resembles the 
frequency of HPA-1a negativity also in other Caucasian populations [1, 9, 138].  
Studies of Caucasian populations of women have shown somewhat different frequencies of anti-
HPA-1a antibody formation in women at risk: from 6 to 12% [8-10]. Anti-HPA-1a alloantibodies 
can be found in primipara women and are detected already at 17 weeks of gestation [10]. Turner et 
al. (2010) also found that 5 of 25 women developed antibodies in second and third trimester at their 
first pregnancy [16]. Kamphuis et al. (2010) report, in their review, that several women were found 
to have antibodies even in the first trimester [139]. However, all women in the last study were 
multiparous, and more typically, anti-HPA-1a antibodies were detected around week 20 of 
pregnancy [140]. 
 
Only one of three delivered infants of HPA-1a negative women with detectable anti-HPA-1a 
antibodies is thrombocytopenic [9]. However, severe thrombocytopenia can occur as early as 16 
weeks of gestation, and there is a relation between antibody level and the severity of 
thrombocytopenia in the newborns [11, 140]. Jin et al. (2019) report in a retrospective study that as 
many as 60% of FNAIT cases were first pregnancies [14].  
 
Anti-HPA-1a antibodies are also associated with reduced birth weight in baby boys [15]. The most 
feared complication of FNAIT is, however, ICH, which is reported to occur in up to 26% of 
retrospective FNAIT cases due to anti-HPA-1a immunization [13], while a review of prospective 




FNAIT is a history of ICH in a previous, affected sibling [4], and most reports agree that pregnant 
women with a previous child with ICH belongs to the highest risk group [141]. If the previously 
affected sibling had ICH, the next affected fetus is likely to have early, severe thrombocytopenia 
and in utero ICH in the absence of effective treatment [142].  
 
The mortality of ICH varies somewhat in the literature. Spencer and Burows (2001), describe a 
mortality of 7% [13], while another literature review, of 246 FNAIT cases, found that 10.2% died 
due to ICH and 15% of the children developed neurological sequelae [143]. Psailia et al. (2009) also 
examined the outcome for 40 cases of ICH in children with immune thrombocytopenia. Fifty 
percent of the children survived with full recovery, 25% survived with neurological sequelae, and 
25% died [144], while Tiller et al. (2013) found that one third of the children died within 4 days 
after delivery and 53% of the children survived with severe neurological disabilities [145]. In any 
case, the outcome of FNAIT-related ICH may in some cases be catastrophic. More children also 
died when signs of bleedings other than petechiae and ecchymoses were present, and petechiae 
were reported in fewer patients with ICH than without ICH [144]. 
 
An observational study of cases from an international multicentre registry characterized pregnancies 
where the fetus or neonate was diagnosed with FNAIT and suffered from ICH [145]. HPA-1a 
alloimmunization was found to be the cause in 91% of the ICH cases. Most of the ICH bleedings 
occurred by the end of the second trimester, and the end clinical outcome was devastating for most 
cases. About half of the bleedings occurred before 28 gestational weeks and often affected the first-
born child (63%), and as many as 67% of the bleedings started before 34 gestational weeks. The 
mothers were primigravida in 27% of index cases. This differs from the finding by Jin et al. (2019), 
who report a frequency of first pregnancies in ICH cases of more than 70% [14]. No cases of 
intrapartum ICH bleedings were confirmed. Antenatal treatment was not given in most cases of 
fetal and neonatal ICH. 
 
Treatment 
Treatment available for HPA-1a immunization in pregnancy is only general and differs between 
countries. In Norway, HPA-1a immunized women are monitored throughout pregnancy, children of 




pregnancy, and compatible platelets are prepared for transfusion when the baby is born [146]. In 
addition to this, women who in a previous pregnancy have carried or given birth to children with 
ICH are also treated with intravenous immunoglobulins (IVIg) during the next pregnancy.  
One way to treat the condition during pregnancy, which is used in some countries other than 
Norway, is to perform fetal blood sampling during pregnancy and transfuse platelets in utero when 
the platelet counts are low. There is, however, an increased risk of fetal loss as a result of these 
procedures. A fetal loss risk associated with the serial of fetal blood sampling and platelet 
transfusions is reported to be of 5.5–6% per pregnancy [12, 147], indicating the clear need for 
further development of less invasive approaches [147].  
 
Other available treatments avoid risk to the fetus from blood sampling by only treating the mother 
with IVIg with or without high-dose steroids [148]. Treatment during pregnancy consists of weekly 
maternal infusions of IVIg beginning at 12–20 weeks of gestation, with or without later addition of 
steroids, continuing until delivery [3, 149]. The response of these treatments is reported to be 
uncertain by Kaplan et al. (1998) [150]. Kamphuis and Oepkes (2011), however, report almost 
100% success with IVIg treatment against FNAIT, with only one or two reported cases of fetal ICH 
despite IVIg treatment [141]. Tiller et al. (2013), found that IVIg treatment failed to prevent ICH in 
only 2 of 19 (11%) cases [145]. Compared with historical data reporting a 79% risk of ICH 
recurrence in FNAIT, their data also indicate that IVIg is effective in preventing ICH, as is also 
reported by Yougbare et al. (2015) in mice [137]. The latter group has also shown previously in 
mice that IVIg downregulates both maternal and the neonatal anti-platelet antibody levels and that, 
in addition to the effect on the antibodies, the FcRn can be blocked by IVIg [137]. In summary, 
IVIg appears to be able to downregulate maternal antibodies both by blocking the Fc receptor on 
trophoblasts and by reducing the antibody titre.  
 
Rayment et al., 2011 [151], did a Cochrane review on the effect of corticosteroid versus IVIg and 
found that the relative risk of death was not significantly different between the two treatment groups 
and that there was no significant difference between mean platelet count at birth [148] or mean 
change in fetal platelet count between pre-treatment and birth in the two groups. In summary, both 
IVIg and prednisone can be used as first line treatment of FNAIT in case of no peripartum 
haemorrhage in an affected sibling when the pre-treatment fetal platelet count is >20. IVIg in 




alone in high-risk pregnancies when the fetal platelet count is <20 or the affected sibling suffered 
ICH [151]. The most important course of action for a neonate with FNAIT and severe 
thrombocytopenia also treated with IVIg during pregnancy is to increase the platelet count as soon 
as possible with compatible platelets [152]. There is no additional gain in adding IVIg postnatally 
[152]. 
 
In absence of a specific treatment for the condition, the Norwegian screening study chose to do 
caesarean sections a few weeks before term to avoid the potential increased risk of ICH by vaginal 
delivery. The safety of vaginal delivery on pregnancies with FNAIT was evaluated through a 
prospective data collection [153]. In FNAIT pregnancies with a thrombocytopenic sibling without 
ICH, vaginal delivery was not associated with neonatal intracranial bleeding. Only four of the 



















Aims of thesis 
Our research group has the privilege to cooperate closely with the National Reference Laboratory of 
Advanced Platelet Immunology. We also benefit from material from a large prospective screening 
study in Norway between 1995 and 2004. As a result of the screening study and many years of 
work, our group has also developed HPA-1a specific T cell clones and an HPA-1a specific human 
monoclonal antibody (“26.4”), useful for further studies on the pathogenesis of FNAIT. Our 
understanding of the pathogenesis of this disease, however, still remains somewhat limited, and 
there are still many missing links in this large puzzle.  
One of the questions still not fully answered is why some women at risk of immunization (HPA-1a 
negative women carrying HPA-1a positive foetuses) are immunized while others are not. In the 
context of introducing a screening for the condition and develop treatment in particular, there is a 
need to more precisely detect the women most at risk of being immunized and in need for treatment. 
In that respect, different HLA alleles have been suggested and shown to be associated with 
immunization and may be used as risk markers. However, some of these results are contradictory. 
In addition, the close linkage between genes in the MHC complex makes it difficult to define which 
of the associations have an impact. The first aim of this study is therefore to investigate the actual 
contribution of different HLA alleles already suggested to be associated with immunization and to 
determine whether carrying different DR-DQ haplotypes associated with the HLA-DRB3*01:01 
allele results in different risks of immunization. 
Missing links may also be found in the placenta, as HPA-1a immunization during pregnancy is a 
break of tolerance against a fetal antigen. In addition, the HPA-1a antigen is present on trophoblast 
cells. The next aim of this thesis is to determine whether HPA-1a specific T cells can also be 
activated by HPA-1a antigen from the placenta, as a possible source of antigen during pregnancy. 
Determining this will have an impact on when to give a potential prophylaxis and will demonstrate 
that pregnant women actually produce an immune response against their fetus under certain 
conditions. 
The third missing link focused on here is the association between the formation of anti-HPA-1a 
antibodies in the mother and reduced birth weight in baby boys. Our third aim is to determine 
whether anti-HPA-1a antibodies may affect adhesion, migration, and invasion of trophoblast cells in 





Summary of papers 
 
Paper I 
The role of Placenta-derived Human Platelet Antigen-1a in HPA-1a alloimmunization. 
Manuscript. 
Heide G, Ahlen MT, Husebekk A, Skogen BR, Stuge TB. 
 
HPA-1a alloimmunization is in most cases believed to occur in connection with feto-maternal 
haemorrhage, where fetal platelets enter the maternal circulation. The highest volume of maternal 
blood entering the fetal circulation takes place at delivery.  
However, it is not known whether the number of platelets entering the maternal circulation during 
pregnancy and at delivery is high enough to cause alloimmunization, and although most women in 
prospective studies seem to be alloimmunized during or after delivery, a considerable percentage of 
women are already immunized during their first pregnancy. Since the HPA-1a antigen that causes 
HPA-1a alloimmunization is found also on trophoblast cells during pregnancy and these cells are 
indeed in direct contact with the maternal circulation and immune system, both as intact cells and 
trophoblast derived vesicles shed into the maternal circulation, it is possible that these cells are also 
responsible for alloimmunization during pregnancy.  
 
Here, we show that HPA-1a antigen from V3 on trophoblast cell lines activates HPA-1a-specific 
T cells in the same way as antigen from platelets, mostly from IIb3, when processed and 
presented by HLA-DRB3*01:01-positive monocytes. The activation of HPA-1a-specific T cell 
clones was dependent on the amount of antigen available for the antigen-presenting monocytes. We 
also show that HPA-1a specific T cells may be activated by HPA-1a antigen-positive extracellular 
vesicles from plasma of HPA-1a positive individuals and pregnant women, and that fetal HPA-1a 
positive vesicles can be detected in maternal plasma of HPA-1a negative women pregnant with an 
HPA-1a-positive fetus. Some of these HPA-1a positive fetal vesicles seem to be of placental origin. 
However, we failed to show that fetal HPA-1a positive isolated vesicles from maternal plasma of an 
HPA-1a negative woman activate specific T cells. Possible reasons for the lack of activation are 




Papers II and III 
The prevalence of HPA-1a alloimmunization and the potential risk of FNAIT depends on both 
the DRB3*01:01 allele and associated DR-DQ haplotypes. Regular article. 
Ahlen MT, Heide G, Husebekk A, Skogen BR, Kjeldsen-Kragh, Stuge TB.  
 
The DR7-DQ2 haplotype in a native Norwegian population. Scand J Immunol 2013 May; 
77(5):429, Letter to the editor. 
Heide G, Stuge TB, Skogen BR, Husebekk A, Ahlen MT  
 
The association between the HLA-DRB3*01:01 allele and HPA-1a alloimmunization is well known, 
as over 90% of immunized women carry this allele. The antigen with leucine in position 33 fits into 
the peptide-binding groove of the MHC molecule, and leucine functions as an anchor residue for 
binding to the MHC complex. It is also shown that our isolated HPA-1a-specific T cell clones are 
restricted by the HLA-DRA/DRB3*0101 molecule.  
 
Another HLA allele, HLA-DQB1*02, has also been shown to be associated with HPA-1a 
alloimmunization, However, HPA-1a specific T cell clones restricted by this molecule have not 
been found, and the molecular explanation for this association is not known. HLA-DRB3*01:01 is 
associated with different HLA-DR-DQ haplotypes in the Norwegian population. The DR3-DQ2, 
which also consist of DQB1*02:01, is one of them. HLA-DQB1*02:01 could therefore be 
associated with HPA-1a alloimmunization simply due to close linkage to the HLA-DRB3*01:01 
allele. Also, DRB4*01 has been suggested to be associated with HPA-1a alloimmunization. This 
allele is also in linkage disequilibrium with DR7-DQ2, the other known DR-DQ haplotype that has 
the DQB1*02 allele.  
 
We genotyped 213 random DRB3*01:01 positive donors from the general population, and 157 
DRB3*01:01 positive HPA-1a alloimmunized women and show that the DR3-DQ2 haplotype is 
overrepresented in this group of immunized women compared to the general population. Most 
important, the prevalence of immunization in HPA-1a negative women is twice as high for women 




indicates that the association with DQB1*02 is due to linkage with DRB3*01:01. However, the 
other DR-DQ haplotype involving DQB1*02, DR7-DQ2 was also seen more frequently among 
DRB3*01:01 positive immunized women compared to the general population. The results suggest 
that the DQ2 allele is not simply acting in synergy with the DRB3*01:01 allele in enhancing the 
chance of HPA-1a alloimmunization. We also find that DRB4*01:01 is infrequent but 
overrepresented in DRB3*01:01-positive women. This association may be coincidental due to the 






















Anti-Human Platelet Antigen (HPA)-1a antibodies affect trophoblast functions and may have 
significance for placenta development: A laboratory study using an in vitro model. Regular 
article. 
Eksteen M, Heide G, Tiller H, Zhou Y, Hersoug Nedberg N, Martinez IZ, Husebekk A, Skogen BR, 
Stuge TB, Kjaer M.  
 
Anti-HPA-1a alloantibodies seem to not only affect the number of platelets in the fetus. Maternal 
anti-HPA-1a antibodies are also associated with clinically significant reduced birth weight in 
newborn boys and with ICH. The integrin β3, carrying the HPA-1 system, not only forms a 
heterodimer with αIIb, it also combines with αV, forming the vitronectin receptor. The vitronectin 
receptor, αVβ3, is expressed on various cell types, including trophoblast cells. It has been proposed 
that the binding of anti-HPA-1a antibodies to antigens expressed on invading trophoblast cells can 
affect the development of placenta, and consequently lead to reduced placenta function and be a 
cause of reduced birth weight.  
 
We aimed here to examine whether interaction of anti-HPA-1a antibodies with antigens on 
trophoblast cells could affect adhesion, migration, and invasion of extravillous trophoblast cells, by 
using an in vitro model with human anti-HPA-1a antibodies and the extravillous trophoblast cell 
line (HTR8/SVneo). The xCELLigence system was used to assess the possible effect of anti-HPA-
1a antibodies on adhesion and migration of HTR8/SVneo cells. Specially designed chambers pre-
coated with Matrigel were used to assess the effect of anti-HPA-1a antibodies on the invasive 
capacity of the cells.  
 
Anti-HPA-1a antibodies partially inhibit adhesion, migration, and the invasive capacity of 














Immunization: what and how, where, and when? 
We start at the very beginning of HPA-1a-immunization. An unknown alloantigen is not sufficient 
by itself to start an alloimmunization process. Alloimmunization requires both a certain amount of 
the foreign antigen, some kind of trigger or danger signal, and that the immune system be well 
enough equipped to make a response. Activation of naive T cells requires properly activated antigen 
presenting cells (APCs), and one of the missing factors in HPA-1a immunization during pregnancy 
is a pro-inflammatory signal. Such a signal is required for maturation of APCs, which in turn 
express key co-stimulatory molecules that allow proper activation of naive T cells. Only subsequent 
to such activation could the same T cells interact with HPA-1a specific B cells, causing the B cells 
to differentiate into anti-IgG secreting plasma cells [154]. We do not know whether the form of the 
antigen matters when it comes to immunization, nor what the secondary, or pro-inflammatory, 
signal in the primary response is.  
 
Regarding HPA-1a immunization, the theory has been that immunization takes place following 
feto-maternal bleeding during pregnancy or at delivery, where the antigen, in the form of platelets, 
enter the maternal circulation. The argument for antigen entrance at delivery might hold for those 
HPA-1a negative women being immunized at birth when the greatest feto-maternal bleeding takes 
place. In RhD immunization, immunization takes place only after a significant trans-placental 
haemorrhage (TPH), and the average TPH at delivery is less than 1 mL of whole blood [32]. If we 
assume, as also reviewed by Curtis [3], a normal fetal platelet count at 18 weeks of gestation and 
assume that platelets do express HPA-1a as early as 18 weeks of gestation [40], an absolute 
maximum of 4 x108 platelets with HPA-1a antigen will be present for the mother’s immune system 
at delivery [3]. If RhD antigen is given intravenously to RhD negative individuals, a primary 
immune response occurs in only 15% of the individuals after 1 mL [32]. It is not known whether the 
amount of platelet HPA-1a antigen entering the maternal circulation at delivery is sufficient to 





For those women immunized during their first pregnancy, the exposure to HPA-1a antigen may also 
come from small repetitive haemorrhages during pregnancy with fetal blood platelets. The amount 
of platelet antigen entering the maternal circulation from haemorrhages during pregnancy will, 
however, be even smaller than by the bleeding at parturition. Since it is uncertain if the highest 
exposure of antigen seen at delivery may cause HPA-1a immunization, it is even more uncertain if 
repetitive small amounts of blood platelets entering the maternal circulation during pregnancy is 
enough antigen for an anti-HPA-1a response to occur. The source of antigen then, may be 
something else than, or in addition to platelets. In that respect, the HPA-1a antigen from αVβ3 
integrin on trophoblast cells is also a potential source of the minor histocompatibility antigen HPA-
1a.  
 
HPA-1a antigen is exposed to the mother`s circulation during pregnancy by the expression of β3 
integrin on ST and EVTs [25, 155] or on shed trophoblast material in form of extracellular vesicles, 
in addition to platelets. Since large amounts of placental cell debris, including from ST, are released 
in different forms and sizes into the maternal circulation during pregnancy [156], the mother may be 
exposed to foreign β3 integrin in large amounts during the whole pregnancy. The β3 integrin, as 
part of the αVβ3, the vitronectin receptor, on trophoblast debris and cells has been proposed as an 
antigen source in HPA-1a alloimmunization. However, it has not been demonstrated that the 
antigen from this receptor, on trophoblast cells, activates HPA-1a-specific T cells. In this project, 
we have shown using β3 integrin from a trophoblast cell line that HPA-1a specific T cell clones are 
also activated with HPA-1a antigen from the vitronectin receptor in extravillous trophoblast cells, 
when processed and presented by DRB3*01:01 positive monocytes. The activation of HPA-1a 
specific T cell clones depends only on the amount of the antigen, and the T cells act in the same 
way regardless of if the antigen source is the vitronectin or the fibrinogen receptor. We also show 
that sorted HPA-1a positive EVs, either alone or bound to dynabeads, when phagocytized, 
processed, and presented by macrophages to T cells, also activate HPA-1a specific T cells. We did 
not succeed, however, in demonstrating that the same specific T cells also could be activated by 
HPA-1a positive EVs of fetal origin in plasma of HPA-1a negative pregnant women. We speculate 
whether this could be because the antigen amount in the experiments were too low, as we only 
immunoprecipitated HPA-1a positive vesicles from a maximum of 4 mL plasma of each pregnant 
woman. The number of fetal vesicles in maternal plasma will naturally be very low compared to 
maternal HPA-1a positive platelet vesicles that we show activates specific T cells. It was also 




vesicles pose some technical challenges that will be discussed later. In addition, the density of 
HPA-1a antigen on ST, and therefore also on debris from these cells, compared to the antigen 
density on the platelet surface is not known but is probably low and most probably much lower than 
on platelets [50, 51, 155]. 
 
Experiments with EVs might be affected by the choice of which women to analyse plasma from. 
HPA-1a positive fetal cells or EVs from plasma of HPA-1a negative immunized women would 
possibly be coated by circulating IgM and complement and removed from circulation [32] and 
thereby no longer be available to the maternal immune system; or to experimenters to isolate for 
further experiments. We therefore chose to use plasma from HPA-1a negative women with low or 
zero antibody titers for our experiments. Vesicles from non-immunized HPA-1a negative women, 
however, may differ from vesicles in immunized HPA-1a negative women in regards to their 
potential to start an immune response.  
 
Given that large amounts of placental material are shed into the maternal circulation during 
pregnancy and that the β3 integrin is present in parts of this material, there should be plenty of 
antigen available for immunization in all HPA-1a negative women carrying HPA-1a positive 
fetuses, despite the likely low antigen density on the surface. The question then relates to why not 
all these women are already immunized during pregnancy. The exposure to the immune system to 
low doses at a time could lead to tolerance in the mother rather than a crucial antibody response. It 
is also believed that placental EVs are part of the communication between the fetus and the mother 
[120]. There is, however, little consensus regarding the effects of the vesicles on immune cells. This 
may be due to different methods used to prepare vesicles in vitro, due to different characteristics of 
the vesicles and to differences in the immune cells examined. The primary mechanism of clearance 
of microvesicles is believed to be phagocytosis [157-159], and vesicles produced in different ways 
by different causes may again have different impact on the phagocytizing macrophages. Abumaree 
et al. (2006) showed that shed trophoblasts were phagocytized in vitro by activated monocytes from 
the U937 cell line [160] and propose that apoptotic trophoblast material induces an anti-
inflammatory response as it induces IDO and IL-10 secretion by the monocytes [160]. The authors 
further show that primary macrophages derived from peripheral blood also could phagocytose 
apoptotic trophoblasts from term placenta and induce the same anti-inflammatory response. In 
addition to this, uptake of apoptotic trophoblast material led to reduced cell surface expression of 




macrophage surface [161], which again may lead to low expression of potential alloantigens to 
specific T cells and further lead to antigen-specific tolerance rather than activation of the T cell. 
Others, however, have shown that MVs may induce pro-inflammatory phenotypes of macrophages 
[162]. In that respect, studies presented here have also found [124] that phagocytosis of apoptotic 
extracellular vesicles results in a downregulation of activation surface receptors on monocytes, 
while phagocytosis of necrotic debris leads to an up regulation of the same receptors and the 
activation of monocytes. 3 negative mice injected with LPS and other bacterial or viral antigens 
and transfused with wild type 3 platelets produced higher levels of anti-3 antibodies compared to 
controls [163]. Mouse pups of immunized 3 negative female mice exposed to the same antigens 
were more thrombocytopenic compared to pups born to uninfected controls [163]. Hence, both the 
amount of antigen taken up at one time, the source of antigen, and the form and presentation of the 
antigen may be of importance for HPA-1a immunization. 
 
There are several feto-maternal interfaces, which again raises the question of where the potential 
immunization against placental antigens actually occurs. Immunization may happen locally in the 
decidua where the antigen is available for the mother both on ST and on invasive extravillous 
trophoblast cells and where maternal immune cells are also present. However, the existence of 
lymph node–like structures in the decidua has never been shown. The characteristics of the maternal 
leukocytes in the decidua is likely also both phenotypic and functionally different from other 
leukocytes [69]. It is also debated whether there are draining lymph nodes from the decidua [71, 
72]. In addition to the local interface, as a second feto-maternal interface, a disruption of the 
trophoblast membrane integrity, as could occur from trauma, infections, or other placental 
abnormalities, may also give rise to intact fetal blood cells in the maternal circulation [3, 164]. By a 
short disruption of trophoblast integrity, fetal cells may transfer to the maternal circulation, and by 
36 weeks of gestation, 100% of women have detectable fetal cells in their circulation [3]. These 
fetal antigens are most likely to accumulate in the maternal spleen [54]. Also, for trophoblast debris 
shed into the maternal circulation that is small enough to be passed the lung capillaries, the logical 
place for potential antigen presentation and activation of specific cells is the spleen.  
 
Finally, when are pregnant women immunized? In the Norwegian prospective screening study, 75% 
of the women were immunized in connection with delivery [8], which again means that 25 of the 




percentage of immunization in primigravida women [2, 10, 14, 16]. In that respect, anti-HPA-1a 
antibodies have been detected in primiparas women as early as 17 weeks of gestation [3, 10]. As 
such, the pregnant women making these antibodies have to be exposed to HPA-1a during early 
pregnancy, in prior undetected or failed pregnancies, or through blood transfusion. The antigen 
may, however, be present for the maternal immune system in the form of V3 from the onset of 
implantation, during the implantation process, and after the placenta is established [27, 28].  
 
HLA-alleles and haplotypes 
Since anti-HPA-1a antibodies are produced, FNAIT must result from an immune response 
involving activation of both T and B lymphocytes. For a B cell to differentiate into an antibody-
producing plasma cell, it needs to interact with the same antigen complex as a T cell specific for the 
same complex [154]. Most humoral responses that involve the switch of isotype from IgM to IgG, 
IgA, and IgE are dependent on T cell support, and only antibodies of IgG type can be transported 
over the placenta in pregnancy [154], being either protective or harmful to the fetus. In that case, T 
cell activation is crucial for the antibody response in HPA-1a immunization, and the T cell response 
is dependent on antigen presentation in an MHC complex.  
 
Almost all HPA-1a alloimmunized women carry the MHC class II HLA-DRB3*01:01 allele. Pooled 
prospective data shows that the odds ratio for becoming anti-HPA-1a immunized is 0.03 for HPA-
1a negative/DRB3*01:01 negative women compared to HPA-1a negative/DRB3*01:01 positive 
women [165]. Recognition of antigen by a T cell is dependent on MHC restriction. The strong 
association between the MHC class II allele DRB3*01:01 and the production of anti-HPA-1a 
antibodies is solid evidence for the involvement of DRA/DRB3*0101-restricted maternal CD4 T 
cell responses in the development of these antibodies, and further FNAIT [154]. The 
DRA/DRB3*0101 molecule is important in presenting the HPA-1a antigen to specific T cells [20]. 
Hence, the association of this allele has a clear molecular explanation. Binding of the HPA-1a 
peptide to the peptide-binding groove of the DRA/DRB3*0101 molecule is mediated by three 
anchor residues, where a small hydrophobic side chain of the Leu33 fits in the small P9 
hydrophobic pocket [21]. The anchoring of Leu33 allows for a broader repertoire of HPA-1a-
specific T cells, and different HPA-1a specific T cell clones have been isolated from one single 
HPA-1a immunized woman [166]. Substitution of the Leu33 with a valine or an isoleucine, which 




PBMC from HPA-1a immunized women with 3 peptides containing the Leu33 residue has been 
shown to result in enhanced T cell proliferation compared to stimulation with peptides containing 
the Pro33 residue [167], and the generation of clonal HPA-1a-specific CD4 T cell lines has been 
reported [20, 95]. However, there is still no formal evidence that these T cells are directly involved 
in supporting antibody responses [154].  
 
Through a literature search of prospective FNAIT studies, the risk of becoming immunized 
postpartum for HPA-1a negative women was estimated at 12.7% in DRB3*01:01 positive women, 
compared to 0.5% in DRB3*01:01 negative women [96]. However, the analysis did not allow 
analysis for nulliparous and multiparous women separately. The results were mainly based on 
results from the Norwegian screening and intervention study, where antibodies were detected in 210 
of 1,990 women, and only 1,182 of 1,990 (65%) women were examined for antibodies postpartum 
[96].  
 
In published studies, there seems to be a closer association between DRB3*01:01 and immunization 
in retrospective cases compared to prospective cases, with an association close to 100% in 
retrospective studies [8, 10, 16, 91, 93]. Our data from prospectively included immunized women 
show a close but somewhat lower association to the allele. This may point to an effect of the 
DRB3*01:01 allele to the severity of the disease. In that case, Kjeldsen-Kragh et al. (2020) find that 
3 of 64 newborns with severe thrombocytopenia of DRB3*01:01 positive mothers suffered ICH, 
while none of the 18 newborns of DRB3*01:01 negative mothers were severely thrombocytopenic 
[165]. In retrospective cases, however, the mother’s DRB3*01:01 carrier status did not significantly 
influence the risk of having a child with ICH [165], nor did Wienzek-Lischka et al. (2017) find that 
the platelet counts in the neonates was dependent on the dose of DRB3*01:01 [91]. This study was, 
however, based on retrospective cases referred to a reference laboratory with generally very low 
platelet counts, indicating a selection towards more severe cases, and a potential dose effect may 
therefore have been missed.  
It is also shown that there is a dose-effect of DRB3*01:01 in HPA-1a immunization: Women 
homozygous for this allele have higher antibody-titre and lower platelet count than women with 
only one DRB3*01:01 allele [97]. The authors presume that APCs with double dose of 
DRA/DRB3*0101 are able to bind more of the antigen than heterozygous cells, thereby offering a 




efficient help to HPA-1a-specific B cells and results in higher antibody levels. Another potential 
explanation for a dose-effect of DRB3*01:01 may be that the increased expression of 
DRA/DRB3*0101, increasing the density of the peptide and HLA-complex on the cell surface of 
homozygous APCs, supports a more productive synapse, resulting in more efficient antigen-specific 
T and B cell activation [168]. The minimum number of TCR-peptide-HLA interactions required for 
T cell activation has been debated [168]. Other studies have shown increased levels of DRB3 
transcripts in homozygous cells [169], and binding measurements of HPA-1a to B-LCLs have 
shown that homozygous DRB3*01:01 cells bind more HPA-1a peptide on their surface than 
heterozygous cell lines [166].  
 
Other alleles shown and suggested to be associated with HPA-1a immunization, are DQB1*02:01 
and DRB4*01:01 [18, 98]. There may be synergistic effects of having two or more alleles on 
enhancing the chance of immunization. The different HLA molecules coded for by these alleles 
may cause different T-cell responses, restricted by different MHC molecules coded for by these 
alleles, acting together, and the activation of more T cells could result in a stronger immune 
response [154]. Because of the strong linkage disequilibrium between genes in the HLA complex, 
and the haplotype blocks the HLA alleles are inherited with, however, it is difficult to determine 
which genes are primarily involved in the associated disease and which genes are only secondarily 
involved only because of their linkage [170]. This again makes it difficult to discover possible 
mechanisms. As such, an association with an HLA allele may not be caused by that specific allele 
itself but rather by another allele or genetic element that is inherited on the same haplotype as the 
specific allele. HLA complex genes, however, most often hold the strongest genetic predisposition, 
and some HLA complex genes seems to be almost necessary, but not sufficient, for the most 
strongly HLA-associated diseases to develop [170], as is the case for DRB3*01:01 in HPA-1a 
alloimmunization.  
 
Loewenthal et al. (2013) found that 13 of 23 immunized women carried both DRB3*01:01 and 
DRB4*01:01 (57%), compared to none in the control group [98]. However, the frequency of 
DRB3*01:01 among women in the control group was already as low as 2 of 24 women, giving a 
very low probability of having both alleles from the beginning. The authors also show, using 
modeling, that the DRA/DRB4*0101 molecule is able to bind the HPA-1a antigen, albeit with 
much lower affinity than the DRA/DRB3*0101. Only those peptides that can form stable 




shown by cellular experiments that peptides in complex with this molecule may activate HPA-1a 
specific T cells. Also, the association to this allele is contradictory, as Labbe et al. (1992) found that 
this allele was actually underrepresented in immunized women compared to non-immunized 
women [18]. Others have also found similar results: that this allele is not overrepresented in 
immunized women [91, 92]. The discrepancy between studies regarding DRB4*01:01 may be 
explained by typing resolution. The allele may, however, also be linked to other gene elements, 
which favours immune response to the HPA-1a alloantigen [101], and thereby only be associated by 
the close linkage to other MHC gene elements.  
 
In continuation of the above, the most probable allele to be associated with immunization, from our 
haplotype data, in addition to DRB3*01:01, is the DQB1*02 allele. Thorsby et al. (1997), suggest 
that genes that to a major extent are responsible in HLA-associations are the genes encoding the 
peptide-presenting HLA molecules [170], and T cells specific to HPA-1a and restricted by HLA-
DRA*05/DQB1*02 is not shown. We speculated that the already known association with DQB1*02 
only was a result of the allele being part of the DR3-DQ2 haplotype, which is one of the DR-DQ 
haplotypes that DRB3*01:01 is in close linkage to. As expected, the DR3-DQ2 haplotype was 
overrepresented in DRB3*01:01 positive women compared to a control group of DRB3*01:01 
positive individuals from the general population. The association with this haplotype accounted for 
about 80% of the DQB1*02 association. However, the other DR-DQ haplotype carrying the 
DQB1*02 allele, DR7-DQ2, was also overrepresented in already DRB3*01:01 positive immunized 
women compared to the DRB3*01:01-positive random population. This suggest that DQB1*02 
actually has a function other than antigen presentation in immunization against HPA-1a.  
Regarding DRB4*01:01, we found that this allele was actually overrepresented in already 
DRB3*01:01 positive immunized women, although not frequently present. For all of the 
DRB4*01:01 positive women in this group, however, the allele came in combination with the DR7-
DQ2 haplotype. In the random population, the DRB4*01:01 allele was distributed on more 
associated DR-DQ haplotypes. Many individuals were also DR7-DQ2 positive without carrying the 
DRB4*01 allele at the same time (data not shown). Hence, although the DRB4*01:01 molecule has 
been shown to possibly bind the HPA-1a antigen with low affinity, the association with this allele 
may be explained by the association with the DR7-DQ2 haplotype in HPA-1a immunization. 
Indeed, the DQB1*02 allele is also overrepresented in immunized women in the work by 




and DRB4*01:01 is not mentioned in their study. Although DQA1*05/DQB1*02-restricted HPA-1a 
specific T cells have not been shown to exist, the existence of such cells cannot be ruled out.  
 
The last allele positively associated with immunization is DRB1*13 [91, 92]. Regarding the 
association both to DRB1*13 and the DR13-DQ6 haplotype, we show that this association is 
positive because of the linkage to DRB3*01:01, and not by the DRB1*13 allele or the DR-DQ 
haplotype in itself. We also show that the prevalence of immunization in DRB3*01:01 positive 
women carrying DR3-DQ2 is twice as high as in women carrying DR13-DQ6, and that the 
prevalence for immunization actually is lower in DRB3*0101-DR13-DQ6 positive women than in 
DRB3*01:01 positive women in general. We therefore also argue that DRB13*01 seems to have no 
function in HPA-1a immunization.  
 
The role of other genetic elements must also be considered, as DR-DQ haplotypes also may be parts 
of extended ancestral haplotypes (AH), also including the MHC part III of the MHC complex on 
chromosome 6. This part of the complex does, by example, contain the part encoding TNF. AH 
8.1, also including DR3-DQ2, is considered to be an “inflammatory haplotype”. A decreased life-
expectancy of 8.1AH carrier women has been found: they have an increased susceptibility for many 
autoimmune diseases, and an association of the AH8.1 class II marker alleles with ovarian cancer 
and breast cancer has also been reported [109]. The AH 8.1, among other alleles contain a TNF 
SNP (TNF-308A) possibly associated with higher levels of TNF in haplotype-positive individuals 
[110]. The role of additional genetic elements in the mentioned haplotype cannot be ruled out.  
 
Effect of anti-HPA-1a alloantibodies 
During placentation extravillous trophoblast cells invade the maternal tissue, including the 
endometrium, the myometrium, and the spiral arteries. Thus, the fetal trophoblast cells invades deep 
into the maternal tissue, and some cells also displace the maternal endothelial cells and smooth 
muscles cells lining the spiral arteries. All these processes are necessary for the development of a 
functional placental unit. In summary, it seems that V3 is an important integrin throughout 
various steps of the making of the placenta, even though depletion of 3 via gene mutation does not 
stop the reproduction process [27]. By hindering some of these processes, one can speculate that the 




be non-optimal. We have shown that anti-HPA-1a antibodies, by the clone “26.4”, do inhibit 
adhesion and migration of the extravillous trophoblast cell line HTR8/SVneo in vitro. Since it has 
been shown that anti-HPA-1a antibodies causes significantly reduced birth weight in boys, we 
suggest that the inhibition of adhesion, migration, and invasion by extravillous trophoblast cells 
during placentation may be one of the causes of this. However, for the anti-HPA-1a antibodies to 
affect placentation, they have to already be present in sufficient amounts during the first trimester, 
when placentation takes place. Anti-HPA-1a alloantibodies are detected already at week 17 [10] in 
primipara women, potentially in time to influence the very last part of placentation but likely too 
late for the antibodies to affect the making of the placenta in a significant way. Other pregnant 
women, however, already have anti-HPA-1a antibodies at the start of pregnancy, after 
immunization at an earlier occasion, that may affect the making of the placenta. The influence of 
antibodies on trophoblast cells were only measured in vitro in our study, by a trophoblast cell line. 
The next step will be to evaluate if the same effect holds also for primary isolated trophoblast cells 
and if different conditions alter the antibody effect.  
 
The antibodies are of IgG type and are therefore transported over the placenta and bind the β3 
integrin on fetal platelets but also bind other cells than platelets that also carry the HPA-1a epitope. 
Other possible mechanisms for anti-HPA-1a antibodies to affect the fetus may be through binding 
of the β3 integrin on fetal endothelial cells. Both platelet-expressed IIb3 and endothelial- and 
tumor cell-expressed V3 participate in angiogenesis, tumor growth, and metastasis [171]. 
Blocking V3, the vitronectin receptor, suppresses endothelial migration during angiogenesis 
[172]. In a mouse model, Yougbare et al. (2015) found that anti-3 antibodies induce ICH in IIb-/- 
pups without thrombocytopenia [137]. They further showed that anti-3 antibodies both inhibited 
angiogenic signalling, induced endothelial cell apoptosis, and decreased the vessel density in 
affected brains and retinas. Most importantly, the data suggested that the impairment of 
angiogenesis is the critical cause of ICH in FNAIT, rather than thrombocytopenia [137]. In that 
respect, Santoso et al. (2016) demonstrated anti-HPA-1a antibodies that only reacted with the V3 
complex in serum from mothers of ICH positive but not from ICH negative FNAIT cases [136], 
resulting both in reduced adhesion of endothelium to vitronectin, cell anoikis, and interference with 
angiogenesis [136]. It that case, is it also interesting that more HPA-1a alloimmunized patients died 
when signs of bleedings other than petechiae and ecchymoses were present together with ICH and 
that petechiae were reported in fewer patients with ICH than without ICH [144]. Also, the positive 




reporting on IVIg in the treatment of FNAIT, about 20% of the fetuses did not seem to respond in 
respect of platelet numbers – their platelet counts remained below 50 [141]. Taken together, anti-
HPA-1a antibodies may be directed only against 3, against the IIb3 complex, or against the 
V3 complex [93, 133, 134, 136, 137], and thereby bind to and affect different cells and tissues, 
resulting in very different clinical effects in the fetus. This variation of anti-HPA-1a antibodies may 
also reflect the primary antigen source in HPA-1a alloimmunization. In that respect, it seems that 
antibodies directed against the V3 integrin have more serious clinical effects, in forms of ICH 
and maybe growth restriction, than antibodies directed only against the IIb3 integrin.  
 
Is there a need for treatment, and who should be treated? 
There is currently no specific treatment for the condition. As described, the treatment available is 
more general and the approach also differs among countries. For severely alloimmunized women, 
there are clear benefits of high dose IVIg administration, where IVIg reduces the risk of ICH in 
subsequent pregnancies [145]. IVIg also reduces the level of circulating alloantibodies in mice 
[137]. In RhD-immunization, this is thought to be mainly due to the negative feedback following 
high total circulating maternal IgG levels [32]. Further benefits of IVIg therapy may include 
interference with transplacental transfer of maternal antibodies by saturation of the trophoblastic Fc 
receptor [32]. However, inhibition of transfer of antibodies to the fetus may also have negative 
effects as the fetus also is protected against foreign antigens by antibody transfer from the mother 
by this receptor. In addition, treatment with IVIg has potential adverse effects [173]. 
ICH caused by HPA-1 immunization also happens in primigravida, as shown by Tiller et al. [145], 
and will not be recognized before the treatment with IVIg is too late to initiate. Severe HPA-1a and 
FNAIT is underdiagnosed in the absence of routine screening [16]. Undoubtedly, even if the 
number of children born with ICH not diagnosed during pregnancy will be low, for those women 
and children exposed, the outcome for the fetus or newborn could be catastrophic. This clearly 
indicates a need to identify pregnancies at risk.  
 
Wilson and Jungners (1968) state nine criteria for screening, also referred to as the WHO criteria 
[174]. Murphy et al. (2002) [175] review these criteria in light of HPA-1a immunization and 
FNAIT. Among those criteria are the following (criteria in italics): The natural history of the 
condition should be known. Regarding the natural history in the mother, HPA-1a negative women 




HLA-DRB3*01:01 is known to increase the risk of immunization; however, the PPV is only 35%. 
We also know that about 10% of HPA-1a negative women produce anti-HPA-1a antibodies. There 
should be a recognizable latent or early symptomatic stage. There is a no defined interval between 
the detection of antibodies in the mother and bleeding signs in the fetus. Accepted treatment should 
be recognized. As discussed earlier, there is no clear approach to antenatal treatment for the first 
affected pregnancy, and the treatment methods differ between countries including for children 
where there is a known previously affected pregnancy, and there is currently no specific treatment 
for the condition. There should be a policy on who should be treated. In the case of HPA-1a 
immunization and FNAIT, this criterion will need further discussion and more precise definition. 
Diagnoses and treatment should be cost-effective. Different research societies have tried to evaluate 
the effect of a potential screening by objectively defining costs and health consequences of a 
hypothetical screening [143] [175]. Case-finding should be a continuous process. This criterion will 
demand a continues national screening of all pregnant women.  
In summary, some criteria will still have to be fulfilled to defend the introduction of a screening 
program. The most important criterion to meet is the development of a safe treatment method for 
the condition. In addition, it will be beneficial to more precisely define which women who are most 
at risk of immunization. While waiting for the screening criteria to be fulfilled, the condition will 
still be under-diagnosed.  
 
A study is ongoing to offer treatment in the form of a hyperimmune anti-HPA-1a IgG prophylaxis 
for the prevention of HPA-1a immunization, resembling RhD prophylaxis [176]. Plasma from 
HPA-1a immunized female donors was collected in the NAITgam donation program. Rallybio 
acquired this NAITgam orphan drug program from Prophylix AS in June 2019 and has proceeded 
with clinical trials. The success in making this prophylaxis will also demand the introduction of a 
screening programme for the condition. In that case, and in continuation of the topic of the above 
paragraph, there is a need to more precisely identify women most at risk of being immunized, who 
will then be selected for further follow up and treatment. Equally important will be to select women 
with a very low risk of immunization who are not in need of further follow up and treatment. It is 
currently known that the DRB3*0101 allele is associated with immunization. Kamphuis et al. 
(2010) found that there is “no HPA-1a immunization” in DRB3*0101 negative women in 98.1% of 
DRB3*0101 negative cases [139], suggesting that DRB3*01:01 negative HPA-1a negative women 
may not need of further follow up, or treatment. As described above, pooled prospective data also 




women compared to HPA-1a negative/DRB3*01:01 positive women [165]. The positive predictive 
value (PPV) of DRB3*01:01 positivity, however, is low (26%) [139]. In addition, in retrospective 
studies the DRB3*01:01 carrier status of pregnant women does not significantly influence the risk 
of having a child with ICH in severely thrombocytopenic children [165]. All studies that could 
narrow the selection of women for follow up are of value. Our HLA-haplotype study is therefore of 
value considering what HLA-associations to further focus on.  
 
Another quite different approach to therapy is to induce tolerance to the HPA-1a antigen. It may be 
possible to tolerize potentially platelet-reactive lymphocytes. The balance between activation and 
tolerization of T cells depends both of the physical nature of the antigen, the state of the MHC, and 
the route of antigen administration. Tolerization is the result of clonal depletion of T cells and 
activation of regulatory T cells. Induction of tolerance to a particular antigen is more efficient prior 
to the immune system’s first encounter with the specific antigen [154]. Sukati et al. (2005), suggest 
that a peptide including the immunodominant 3 epitope mapped may be used as a basis for the 
induction of tolerance to the HPA-1a antigen [177]. It has been shown in rodent models, that a 
peptide containing a dominant T cell epitope can prevent responses to the corresponding antigen 
when given by a tolerogenic mucosal route [177].  
 
Last, we know that in most HPA-1a negative women pregnant with an HPA-1a positive fetus, even 
in combination with DRB3*01:01 positivity in the mother, anti-HPA-1a alloimmunization does not 
happen. Placental debris and extracellular vesicles may have characteristics that make them 
harmless under normal conditions. Increased knowledge of fetal extracellular vesicles in maternal 
circulation, their characteristics, and their impact on both the mother’s antigen-presenting cells and 
T cells may not only help in understanding the break of tolerance in HPA-1a immunized women but 









In vitro activation of HPA-1a specific T cell clones  
In vitro cell culture systems can never completely mimic biological environments and systems, and 
in vivo T cells will always be under the influence of many more factors and cells than the cells in 
the cell culture system. This is also the case for HPA-1a specific T cell clones isolated from 
peripheral blood of HPA-1a alloimmunized women. However, the HPA-1a specificity and HLA-
DRA/DRB3*0101 restriction also holds for in vivo functions of the T cells.  
 
HPA-1a specific T cell clones were activated in our study by the presentation of HPA-1a antigen by 
DBR3*01:01 positive monocytes both from trophoblast and platelets. To ensure that the antigen 
amount given to monocytes for processing and presentation was high enough to cause activation of 
the specific T cell clones used, the trophoblast cells were lysed and β3 integrin was immune-
precipitated on epoxy dynabeads before being given to monocytes. In that way, we were able to 
measure and estimate the relative antigen amount actually immune-precipitated from both antigen 
sources for comparison. Macrophages are able to phagocytize both dynabeads and latex beads 
[178], and the principal receptor to govern phagocytosis is the FcR. The macrophages will process 
the uptake and present peptides in MHC on the surface. Phagocytosis of dynabeads can be 
visualized by a light microscope, as the dynabeads are brown, and some monocytes may be fully 
packed with brown beads. The indirect proof of phagocytosis is, however, the activation of the T 
cell clones, which requires phagocytosis, processing of the phagocytised material, and presentation 
of peptide by the monocytes. The monocytes cannot process dynabeads, and it is possible that the 
phagocytosis of numerous beads will somehow reduce the capacity of monocytes to process and 
present antigens, in addition to potentially also causing activation of the APCs. Since in this case 
the goal was to compare activation of T cells by HPA-1a antigen from platelets and trophoblast 
cells, and the same approach in respect of numbers of beads and volumes was used for both these 
cell types, we avoided these problems. The different T cell clones used reacted different to antigens 
with respect to the amount of antigen needed for activation and the degree of activation measured 
by production of TNF or IFN. However, the clones did not differ between antigens from 





The overall goal of this project was to demonstrate that HPA-1a antigen from trophoblast cells is 
able to activate HPA-1a specific T cell clones in the same way as HPA-1a antigen from platelets, 
following the idea that trophoblast debris, forming extracellular vesicles in different forms and 
sizes, carries the antigen and is therefore a potential carrier of antigens to monocytes. To 
demonstrate that HPA-1a positive placental microvesicles in maternal HPA-1a negative plasma also 
activate HPA-1a specific T cell clones would be optimal and was the main goal. We were not able 
to demonstrate that fetal microvesicles isolated from maternal plasma activate HPA-1a specific T 
cells. However, we were able to demonstrate that HPA-1a positive vesicles isolated from HPA-1a 
positive plasma may activate HPA-1a specific T cells, when taken up, processed and presented by 
monocytes, which also indirectly demonstrates that macrophages phagocytize microvesicles. In 
addition, we demonstrate that there are HPA-1a positive vesicles in plasma of HPA-1a negative 
women pregnant with an HPA-1a positive fetus.  
 
We were able to sort fetal HPA-1a vesicles from maternal HPA-1a negative plasma both by FACS 
and by anti-HPA-1a coupled dynabeads and tried to activate T cell clones by this material, without 
success. We suggest that the reason for this is that the amount of antigen isolated is too small for the 
T cells to be activated. T cells were activated by antigen bound to beads from 4 mL plasma of an 
HPA-1a positive individual (5x105 beads) and by 6x104 sorted positive vesicles directly from an 
HPA-1a positive individual. The fetal HPA-1a positive vesicles sorted and the number of vesicles 
bound to beads from HPA-1a negative pregnant plasma were expected to be very low, as also 
shown by the detection of very few HPA-1a positive events in plasma of HPA-1a negative women 
with HPA-1 positive fetuses. 3 expression on non-platelet vesicles in plasma is also probably 
much lower than on platelet vesicles. Unfortunately, we did not find a good approach to conclude 
on the amount of antigen given to T cells in those experiments, in part because the total amount of 
material working with was low. By using vesicles from HPA-1a positive plasma, however, we are 
able to isolate a sufficient number of vesicles for activation. Also, since it is proposed that vesicles 
made under different conditions is able to make different responses in phagocytizing monocytes, it 
could be of interest to sort extracellular trophoblast vesicles in equal parts, by example, of necrotic 
and apoptotic vesicles to evaluate the potential different effect on activation of T cells. Because of 
technical challenges when working with microvesicles, and limited access to pregnant plasma, this 





Working with T cell clones, and also with other living cells such as monocytes and platelets, is also 
challenging. The T cell clones are not transformed T cells. Hence, they will lose their ability to 
divide and they have limited life-time, and have to be re-stimulated and expanded regularly [166]. It 
is time consuming and challenging to keep the cells going, and to have cells available and healthy at 
the time of experiments. Monocytes also had to be isolated prior to each experiment, and was used 
fresh, or after 3 days in culture. The need for monocytes being DRB3*01:01 positive and HPA-1a 
negative was also somewhat limiting for the frequency of performing experiments.  
 
Technical challenges when working with extracellular vesicles 
Extracellular vesicles come in many different forms and sizes, and the isolation protocols used in 
the literature seem also to differ greatly. Our main question was to answer whether fetal 
extracellular material shed into maternal circulation from the placenta could activate HPA-1a 
specific T cells when taken up, processed, and presented by maternal monocytes. For our purpose, 
and also to be able to characterize the vesicles in flow cytometry, we chose not to isolate the 
smallest vesicles. Also, we assumed that the microvesicles shed from ST would be the vesicles with 
most antigen on the surface as they are made by blebbing of the membrane of the host cell. Our 
isolation method was therefore easy and only included centrifugation at 17,000 x g, after removing 
platelets with centrifugation in two steps. Electron microscopy and flow cytometry analysis showed 
that vesicles were isolated by this approach. The HPA-1a positive vesicles were further isolated 
from all the other vesicles either by incubation with 26.4-coupled dynabeads or by sorting 26.4-
positive vesicles in the FACS.  
 
Characterization of the isolated vesicles in flow cytometry proved challenging, and during the time 
of the project, the field also has developed significantly. One of the challenges is to be sure that the 
vesicles analysed are indeed single events. The term “swarm detection” describes the fact that 
several particles are detected as one by the flow cytometer. This could involve several small 
vesicles being detected as one. There are, however, methods for demonstrating single particle 
analysis. By serial dilutions of a sample of single particles, the number of positive events will halve 
while the fluorescence intensity of positively stained particles should remain consistent [179]. We 
stained different dilutions of vesicles in our experiments, showing that the mean fluorescence 
intensity remained stable with the decrease of vesicles per ml. Goergens et al. (2019) attempted to 




using CD63eGFP-labelled extracellular vesicles as a reference material [180] and found that within 
a range of 2x106 and 3x107 extracellular vesicles per ml there is a linear decrease with higher diluted 
samples while the mean fluorescence intensity values remain stable; within this concentration 
range, mostly single extracellular vesicles were detected. All our experiments were also done with 
low flow/min and with few events (EVs) per ml. If the main goal in our flow experiments with 
vesicles was to demonstrate that fetal HPA-1a positive vesicles can be found in plasma of an HPA-
1a negative pregnant woman, however, swarm detection would not influence the result. If we rather 
were to say anything about the amount of such vesicles isolated, swarm detection could potentially 
have had an influence. In addition, when staining for several surface markers with two or more 
specific antibodies, what appears to be one vesicle positive for two surface markers, may actually 
be two separate vesicles, each positive for one of the two markers. Again, in our experiments, we 
did not primarily seek to quantify the number of vesicles. In addition, we used only HPA-1a as a 
positive surface marker and CD41 and CD14 as negative markers, avoiding the potential problem of 
two vesicles positive for each positive marker appearing as one vesicle positive for both markers.  
 
Detection of events that are not truly vesicles could also be due to other particles from buffers, or 
immunoprecipitated antibodies, appearing as vesicles by analysis. Very large differences between 
individual antibodies in terms of antibody-related background has been described [180]. Antibody 
in buffer should be one of the controls. Others have also used filtration of both buffers and 
antibodies to avoid the risk of false positive vesicles by bigger particles in the buffers [181]. 
Staining for each antibody should be shown individually, and isotype controls are not suitable to 
control for false positive events in EV flow cytometry [180]. The experiments with vesicles were 
done some years ago. In presenting our results, however, we have tried to follow the MIFlowCyt-
EV guidelines published in 2020 [182]. This is a framework for the minimum information that 
should be provided regarding the flow analysis of extracellular vesicles, developed by a working 
group of researchers working with extracellular vesicles in flow cytometry, built on both Minimum 
Information for Studies of EVs guidelines (MISEV) [183] and Minimum Information about a Flow 
Cytometry experiment standard (MIFlowCyt) [184]. The use of this guideline has been of great help 
in analysing and presenting flow cytometry results.  
 
By using another method, we could also potentially determine how many vesicles are needed for 
activation of an HPA-1a specific T cell. A given number of positive vesicles from antigen positive 




form of trophoblast vesicles due to lower protein expression on the surface. In addition to the 
assumed low expression of HPA-1a antigen on ST microvesicles, we also expect that the expression 
will differ between trophoblast vesicles, reflecting the areas with or without the expression of the 
antigen on the mother cell, and this is an obvious challenge when trying to detect so few fetal HPA-
1a positive vesicles in maternal plasma.  
The “amount of fluorescence light a flow cytometers detector receives is dependent on the 
fluorophore’s emitted power (brightness), the number of fluorescent molecules being 
illuminated, the flow cytometer`s laser intensity, and the characteristics of the optical 
components between the fluorophore and the detector” [179].  
Larger EVs’ expression of multiple copies of the antigen of interest will enable separation from the 
auto-fluorescent population. As EVs decrease in diameter along with the surface area with limited 
expression of the antigen, the fluorescent populations will decrease [179]. The instruments will not 
be capable of determining the protein expression of smaller EVs. Hence, the EVs characterized in 
our experiments were not the smallest microvesicles, and the fluorescence intensity was low, both 
because the vesicles were small and because the antigen is expressed at a low level. For fetal HPA-
1a positive vesicles in HPA-1a negative pregnant plasma that we show, assumed to be of placental 
origin, the fluorescence intensity was low (much lower than the intensity from platelet vesicles). In 
addition, the intensity varied between vesicles, as expected.  
 
The extravillous cell line HTR8/SVneo as a model cell line 
To evaluate if anti-HPA-1a antibodies affect trophoblast function we used the extravillous 
trophoblast cell line HTR8/SVneo. We hypothesized that anti-HPA-1a antibodies somehow affect 
trophoblast function and thereby alter placentation in HPA-1a alloimmunized women, since anti-
HPA-1a antibody formation was associated with significantly reduced birth weight in boys [15]. 
Invasion of the uterus wall starts by implantation of the blastocyst and continues until remodelling 
of the spiral arteries [23]. During this period, the migration and invasion of extracellular trophoblast 
cells are important for developing a functional placenta for further nourishment and growth of the 
fetus. We needed a cell line that was isolated from the time of placentation, when invasion takes 
place. Graham et al. (1993) [185] established a first trimester human trophoblast cell line, the 
HTR8/SVneo, by transfecting normal first trimester trophoblast cells with a plasmid containing the 
gene for the simian virus 40 (SV40) large T antigen (Tag). Expression of different surface integrins 
also differ along gestation. To be able to evaluate the potential effect of our anti-HPA-1a antibody, 
the cell line used also necessarily needed to express the β3 integrin on the surface. HTR8/SVneo 




previously that our anti-HPA-1a antibody, “26.4”, binds the HPA-1a epitope on this receptor with 
even better affinity than to the fibronectin receptor on platelets [186]. The problems with this cell 
line, also discussed by others, is that it does not quite resemble extravillous trophoblast cells in all 
aspects, as it for example does not express the extravillous cell marker HLA-G and also shows low 
expression of the vitronectin receptor. In addition, the cell line may have altered its characteristics 
after several passages in culture.  
 
HLA allele typing, and what is what in associations with disease?  
As already discussed, the general problem with HLA and haplotype associations in disease is to 
interpret the result for single HLA alleles because of the close linkage between genetic elements in 
the MHC complex. In that respect, the DQB1*02 allele has actually been associated with HPA-1a 
immunization for several years [18]. Despite this, however, and probably because of the lack of a 
molecular explanation of the association, it seems that the association is believed to be found 
because of the close linkage to the DRB3*01:01 allele. In fact, this was also our assumption when 
starting the HLA project. To more precisely define which alleles will increase or decrease the risk 
of immunization, our preferred control group will be a group of HPA-1a negative women not 
immunized during or after pregnancy. Only such a control group will give the possibility to say 
anything about the risk of immunization by carrying specific alleles. In the absence of such a 
control group, we compared only individuals that were positive for the allele already known to be 
truly associated with immunization, DRB3*01:01. By comparing only those individuals, we were 
able to examine what other alleles that also might be associated. And our results seem to point to an 
actual effect of the HLA-DQB1*02 in HPA-1a immunization. Before the potential effect is 
demonstrated, however, the actual association will be debated. As is also the case for DRB4*01:01. 
In addition, results from the Norwegian screening study, together with our own results, also gave us 
the possibility to calculate the prevalence of HPA-1a immunization when carrying different 
DRB3*01:01 associated DR-DQ haplotypes.  
 
The results we present for haplotypes were “interpreted using the set of alleles known at the start of 
the project” [100], over 10 years ago. Presenting and publishing data now, the methods we have 
used for HLA typing are both old and time-consuming. New HLA alleles are detected all the time 
as are new combinations of HLA DR-DQ haplotypes. Despite the fact that many of these alleles are 




methods we may have mistyped some of our participants in the HLA study and lost one rare HLA 
allele. However, it is not likely that this will have affected the interpretation of our main results and 
our main questions in the study.  
 
We have used published known DR-DQ haplotypes in the Norwegian population [105, 106] and 
focused on the most common ones in assembling the haplotypes of each individual, based on typing 
of single alleles. New HLA haplotype frequency reference standard in European Americans (2003) 
revealed that the frequency distribution of the 75 haplotypes was right-skewed and that only 16 
haplotypes occurred at a frequency >1% [100], defending our approach for assembling haplotypes. 
The authors also measured the probability of an accurate allele assignment for the DQ portion of the 
haplotype if only the DRB1 allele had been typed (that is, the probability of assigning the most 
commonly occurring DQ haplotype for each DRB1 allele). As an example, the DRB1*0301 allele 
appears at a frequency of 13.19%, and exists in two DRB1-DQA1-DQB1 haplotypes, and the 
frequency of the most common of these is 99.6%. The DRB1*1301 allele appears at a frequency of 
5.66%, existing in four haplotypes, and the frequency of the most common is 98.1% [100].  
 
Our control population consisted of random blood donors from the University Hospital of North 
Norway, Tromsø, and the ethnicity of those donors was not known. The Norwegian population is 
predominantly Caucasian. However, Tromsø is the town in Norway with most self-registered Sami 
people. Without using much time and space to discuss the criteria of being registered as Sami in 
Norway (there is no such official register), it is possible that a significant number of Sami among 
our control population may have affected the haplotype distribution in the control group. We know 
that frequencies of HLA alleles and haplotypes in Sami differ from the Norwegian population 
[107]. Also, a lower total number of alleles were detected in the Sami at some loci: HLA-B, -C, -
DRB1, which could be a result of genetic drift. Linkage disequilibrium between HLA loci was 
generally also found to be higher in Sami than in non-Sami Norwegian – which is also a sign of 
genetic drift and isolation in the Sami [107]. Both the frequency of HLA-DQB1*02 and HLA-
DRB3*01:01 in our control populations, however, matches the frequency of these alleles in other 






HPA-1a alloimmunization in pregnancy is related to platelets, both considering the cause and the 
effect of the immunization. However, we should not only blame the platelets. The HPA-1a antigen 
is not dangerous for women at risk without the wrong MHCs able to present the antigen to T cells 
crucial for the antibody response in HPA-1a immunization. We have shown that exactly what DR-
DQ haplotype the DRB3*01:01 comes with also influences the prevalence of immunization. It may 
also be dangerous for the fetus that the antigen is also presented on trophoblasts, that the HPA-1a 
antigen is visible for the mother during the whole pregnancy in forms of extracellular vesicles, and 
that the anti-HPA-1a antibodies affect the trophoblast cells during important periods of placentation 
and bind to endothelial cells and cause ICH during pregnancy. It may be that the platelets and the 
thrombocytopenia in itself are not excessively dangerous.  
 
Future perspective 
A new prospective study including screening of all pregnant women would benefit from HLA 
typing of all HPA-1a negative women, including those not immunized. This will help to more 
precisely define which HLA-alleles actually make a difference in immunization, and may help both 
in revealing the immune mechanisms in HPA-1a immunization and in detecting women most at 
risk, both for immunization and for ICH. To be able to say anything about the risk of immunization 
due to carrying the different HLA alleles, the study should also include the gravida- and para-
history of all women prior to their entry into the study, and all women should be followed for 
several years. A new prospective study should also preferentially include detection of antibodies 
both against 3 integrin, IIb3 integrin complex, and V3 integrin complex. 
 
The potential effect of anti-HPA-1a antibodies on trophoblast function may further be studied in 
vitro both using different first trimester trophoblast cell lines in addition to first trimester 
trophoblast cells isolated from pregnant women. Considering the growing knowledge of the variety 
of anti-HPA-1a antibody-specificities, both antibodies against the 3 integrin, the IIb3 complex, 





To answer if HPA-1a positive fetal vesicles in plasma of HPA-1a negative women carrying HPA-1a 
fetuses activate T cells will probably be possible only by increasing the amount of isolated HPA-1a 
positive vesicles, further using the same T cell assays as already described. It would be helpful to 
somehow be able to estimate the ratio of the 3 integrin expression on microvesicles of both platelet 
and trophoblast origin and to calculate the approximate number of trophoblast vesicles that express 
the same amount of integrin as one platelet vesicle. Characterization of other markers on HPA-1a 
positive fetal vesicles in plasma, in addition to definition of vesicle size will also be important to 
evaluate potential variable effect of different types of vesicles on immune cells, and will likely need 
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Abstract
Alloimmunization against human platelet antigen (HPA)-1a during pregnancy can 
cause foetal/neonatal alloimmune thrombocytopenia (FNAIT) and severe bleeding 
in the foetus or newborn and likely depends on several factors. HPA-1a alloimmun-
ization is associated with DRB3*01:01, which is associated with several DR-DQ 
haplotypes. However, it is not known to what extent these haplotypes contribute 
to the prevalence of HPA-1a alloimmunization. HPA-1a–alloimmunized women, 
identified in a prospective study, and random donors were typed for selected DRB3, 
DRB4, DRB1, DQA1 and DQB1 alleles to determine allele and DR-DQ haplotype 
frequencies. DRB3*01:01 was carried by 94% HPA-1a–immunized women com-
pared to 27% in the general population. In the first population, the DR3-DQ2 haplo-
type was overrepresented (P < .003). The prevalence of HPA-1a alloimmunization 
was estimated to be about twice as frequent with DR3-DQ2 compared to DR13-DQ6, 
together accounting for about 90% of DRB3*01:01–positive individuals. Further, 
we examined DQB1*02 and DRB4*01:01 alleles for their reported association with 
HPA-1a alloimmunization, in the context of DR-DQ haplotypes. Since  ~  80% of 
DQB1*02 alleles are linked to the DR3-DQ2 haplotype, the association might be 
coincidental. However, the DQB1*02:02–associated DR7-DQ2 haplotype was also 
overrepresented in alloimmunized women, suggesting a role for this allele or haplo-
type in HPA-1a alloimmunization. As DRB4*01:01 is predominantly associated with 
the DR7-DQ2 haplotype in HPA-1a–alloimmunized individuals, the reported associ-
ation with FNAIT may be coincidental. Typing for DR-DQ haplotypes revealed im-
portant genetic associations with HPA-1a alloimmunization not evident from typing 
individual alleles, and the presence of different DRB3-associated DR-DQ haplotypes 
showed different prevalence of HPA-1a alloimmunization.
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1 |  INTRODUCTION
FNAIT is a rare condition that can cause severe complications 
such as intracranial haemorrhage in the foetus or newborn 
due to the transfer of platelet-depleting alloantibodies from 
the mother to the foetus during pregnancy. The most common 
cause of FNAIT is maternal alloantibodies directed against 
HPA-1a on foetal platelets. This fetomaternal incompatibility is 
defined by a leucine/proline polymorphism at residue 33 in in-
tegrin β3.1 About 2% of Caucasian women are homozygous for 
the HPA-1 variant with proline (HPA-1bb). Alloimmunization 
occurs in about 10% of these women,2 and about one third of 
these will give birth to a child with FNAIT. The most severe 
complication is intracranial haemorrhage (ICH), which occurs 
in approximately 1 in 10,000 unselected pregnancies.2 Several 
factors may in theory affect the natural history of FNAIT, as 
reviewed by Sachs and Santoso (2017),3 including the influ-
ence of the maternal HLA class II genotype. The MHC class 
II allele HLA-DRB3*01:01 is strongly associated with HPA-1a 
alloimmunization; more than 90% of immunized women carry 
this MHC allele,4-6 which also shows a dose-dependent asso-
ciation to the severity of HPA-1a immunization.7 This strong 
genetic association suggests that HPA-1a immunization is de-
pendent on T cells restricted by the MHC class II molecule 
encoded by the HLA-DRA/DRB3*01:01 alleles. There is sup-
port for this notion: HPA-1a– but not HPA-1b–derived peptides 
bind this molecule, and the allogeneic residue Leu33 serves to 
anchor the peptide.8,9 Furthermore, HPA-1a–specific CD4+ T 
cell clones have been isolated from alloimmunized women,10-12 
and these T cell clones are restricted by DRA/DRB3*01:01.10 
However, it is possible that there exist additional genetic fac-
tors that predispose for immunization. In that respect, both 
DQB1*02 and DRB4*01 have been shown to be associated 
with FNAIT.1314 However, these alleles and other genetic el-
ements that may influence HPA-1a alloimmunization do not 
segregate entirely independently of each other. Rather, they are 
in linkage disequilibrium with other genes in conserved hap-
lotypes. In this respect, the DRB3*01:01 allele is known to be 
in linkage disequilibrium with several different DR-DQ haplo-
types, and one of these contains a DQB1*02 allele.15,16
In the present study, we aimed to examine the impact of 
DRB3*01:01–associated DR-DQ haplotypes on HPA-1a 
alloimmunization, and to determine the haplotype associ-
ations and relative importance in HPA-1a alloimmuniza-
tion for HLA-DQB1*02:01/*02:02 and HLA-DRB4*01:01 
alleles.
2 |  METHODS
The study was approved by the Regional Committee for 
Medical Research Ethics, North Norway (approval no. P 
REK NORD 66/2005, 2009/1585 and 2012/1917). Blood 
samples were drawn from patients and healthy volunteers 
after written informed consent.
2.1 | Study groups
In total, 167 HPA-1a–immunized women were included in 
the study comprising two different populations: one group of 
HPA-1a–negative women who developed anti-HPA-1a IgG 
antibodies in connection with pregnancies, included from the 
Norwegian prospective FNAIT screening study (1995-2004) 
(prospective screening group, N = 123)4 ( More than 2/3 of 
these immunized women were included from the southern 
part of Norway), and one group of women referred to the 
Norwegian National Unit for Platelet Immunology (NNUPI) 
after giving birth to a child with severe thrombocytopenia 
and clinical signs of bleeding, also producing anti-HPA-1a 
IgG antibodies (retrospective group, N = 44). The criteria for 
inclusion of both subgroups were detectible levels of anti-
HPA-1a antibodies.
The control group was made of 781 healthy random 
blood donors at the University Hospital of North Norway, 
referred to as the general population. No information re-
garding ethnicity was available for neither the random do-
nors nor the immunized women. The Sami population is 
known to differ from the Norwegian population in several 
HLA types.17 However, most individuals were expected to 
be Caucasians in both groups as all donors were recruited 
from the Norwegian population, and not from specific 
Sami areas of Norway. The frequency of DQB1*02 in our 
control population also fits the frequency of DQB1*02 in a 
group of about 8000 Norwegian donors at the bone marrow 
registry (32,6%), lending support to the notion that the con-
trol population in this study reflects the general population 
in Norway.
2.2 | DNA isolation
Cryopreserved genomic DNA was available from about 40% 
of the HPA-1a–alloimmunized women. In addition, DNA 
was isolated from blood samples from the rest of alloimmun-
ized women and all randomly selected donors, using Blood 
Mini Kit (QIAGEN) and eluted in sterile H2O. Short-time 
storage of DNA was carried out at −20ºC whereas −70ºC 
was used for long-time storage.
2.3 | Genotyping
Primer sequences, characteristics and cycling programs are 
listed in supplementary data (Tables S1 and S2). All primers 
were synthesized by Eurogentec (Belgium). All PCR were 
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performed in a total volume of 25µL, using 0.5U HotStarTaq 
(Qiagen) per reaction, and run on a GeneAmp9700 (Applied 
Biosystems). HGH was used as an internal DNA amplifica-
tion control.18 Genomic DNA from IHWG cell lines was 
used as controls for amplification, specificity and enzyme 
digestion: STEINLIN, DUCAF, EMJ, LZL, CEPH-1413, 
HAG, BER, WDV and EK (Table S3).
Restriction cutting of PCR products was performed with 
endonucleases (all from New England Biolabs) according to 
references (Table S2).
The risk of false-positive detection within each genotyp-
ing assay, for example amplification of infrequent alleles by 
group-specific primers, could be evaluated by conferring 
dbMHC (the MHC database) with updated sequences.
2.3.1 | Designation of HLA-DR-
DQ haplotypes
HLA-DR-DQ haplotypes for each donor were designated 
based on known DR-DQ haplotypes in the Norwegian popu-
lation,15,17,19 based on typing of selected DR- and DQ alleles. 
To answer our main questions in this study, alleles known to 
be associated with DRB3*01:01 and DQB1*02 were specifi-
cally typed for (Table 1).
2.3.2 | Detection of DRB3*01:01P
Detection of DRB3*01:01P (http://hla.allel es.org/allel es/p_
groups.html) was performed for all immunized women and 
random donors by PCR using sequence-specific primers 
for DRB3*01:01/*03:01,20 combined with restriction frag-
ment length polymorphism (RFLP) by the enzyme KpnI, 
cutting amplified DRB3*01:01, but not DRB3*03:01. All 
DRB3*01:01–positive random donors (213) and immunized 
women (157) were included for further detection of HLA-DR 
and –DQ alleles.
Because the above-mentioned method of DRB3*01:01 
detection is both time- and resource demanding, we also 
developed a new DRB3*01:01 typing assay. This assay 
was performed for almost all individuals as duplex assay 
for DRB3*01:01 and GAPDH in a TaqMan RQ-PCR 
assay on genomic DNA: 10 to 100 ng DNA was used in 
25 μL reactions, in parallel reactions, with TaqMan Fast 
Universal PCR Master Mix, run on Fast mode (95°C for 
20  seconds followed by 40 cycles of 95°C for 1  second 
and 60°C for 20 seconds) on ABI Prism7900HT (Applied 
Biosystems).
Oligos for HLA-DRB3: HLA-DRB3 primers (1000nM) 
5’- TCTTGGAGCTGCGTAAGTCTGA-3’, 5’-TGTTCCAG 
GACTCGGCGA-3’ and a specific HLA-DRB3*01:01 
probe (150  nM) 5’-6-FAM-TCTPTCCAGGZACCG-BHQ- 
1-3' (P= G-LNA, Z=T-LNA nucleotides). For GAPDH as 
reference, primers (500nM) 5’-CCCCACACACATGCACT 
TACC-3’, 5’-CCTAGTCCCAGGGCTTTGATT-3’ and a 
probe (100nM) 5’-VIC-AAAGAGCTAGGAAGGACAGGC 
AACTTGGC-BHQ-1-3’. Samples from fully HLA typed 
cell lines were used as controls for method development: 2 
copies of DRB3*01:01 (STEINLIN), 1 copy of DRB3*01:01 
(D4BL4 in-house), as well as DRB3*01:01–negative, 
DRB3*02:02/DRB3*03:01–positive samples (DUCAF/
EMJ).
2.3.3 | Detection of DQB1*02 and DQA1*05
Group-specific primers for DQB1*02 and DQA1*05 were 
multiplexed.21,22 The primers for DQA1*05 and DQB1*02 
theoretically amplify all alleles in the two different groups. 
To discriminate between the allele DQB1*02:02 and other 
DQB1*02 alleles, typing for DQB1*02 23 was combined with 
digestion by the restriction endonuclease MscI, cutting only 
the amplified product of DQB1*02:02 in exon 3 of the DQB1 
gene.
2.3.4 | Detection of DRB1*03:01, 
(*11:01/*11:02), *13:01, *13:02, *13:03, 
(*14:01)
Group-specific primers for two groups of alleles were used.24 
Primers for Group-1 amplified DRB1*11:01, *13:02, and 
*13:03. The restriction endonucleases, FokI and SfaNI, were 
Haplotype DRB1 DQA1 DQB1 
Additional DRB 
association
DR3- DQ2 *03:01 *05:01 *02:01 DRB3*01:01
DR13(01)- DQ6 *13:01 *01:03 *06:03 DBR3*01:01
DR13(03)-DQ3 *13:03 *05:01 *03:01 DRB3*01:01
DR7- DQ2 *07:01 *02:01 *02:02 DRB4*01
DR7- DQ3 *07:01 *02:01 *03:03 DRB4*01
All alleles are written in italic. Alleles specifically typed for in this study are in bold.
T A B L E  1  Common HLA alleles and 
HLA DR-DQ haplotypes in the Norwegian 
population, specifically typed for in this 
study. Adapted from Spurkland et al, 
Harbo et a and Lande et al,15,17,19 with 
modifications in DRB1*1331
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used to distinguish between these three DRB1 alleles. Primers for 
Group-2 amplified DRB1*03:01, *11:02, *13:01, and *14:01. 
The restriction endonucleases FokI, SfaNI and KpnI were used 
to distinguish between these alleles. For details, see Table S2.
2.3.5 | Detection of DRB1*07
Detection of DRB1*07 was done by group-specific PCR for 
DRB1*07.25
2.3.6 | Detection of DRB4*01:01
Two sets of primers and restriction endonucleases, for exon 
2 and exon 3, were used. The first group-specific primers 
for DRB4*01 in exon 2 amplify all DRB4*01 alleles except 
DRB4*01:05.26 Samples positive in the first PCR were fur-
ther typed for exon 3, with primers specific for DRB4*01:01, 
-*01:02, -*01:03, -*01:06, -*02:01, and -*03:01.27 The 
restriction endonuclease EaeI cuts DRB4*01:01 and 
DRB4*01:06. Hence, samples with amplified products in 
both reactions and only restricted by the EaeI enzyme could 
be DRB4*01:01 and/or DRB4*01:06 positive.
2.3.7 | Confirmation of haplotypes and 
additional haplotype detection
To support the assigned DRB3*01:01–associated haplotype, 
for each immunized women and each individual in the con-
trol group, based on the results of PCR-RFLP genotyping 
and to uncover the additional haplotype, low-resolution typ-
ing for DRB1 was performed by the Norwegian Bone Marrow 
Registry in Oslo, Norway; donors were typed for HLA-DRB1 
by oligonucleotide probing defining HLA-DR1, DR2, DR3, 
DR4, DR7, DR8, DR9, DR10, DR11, DR12, DR13, DR14 
and DR103 specificities. Due to too low amounts of DNA, 
some donors could not be low-resolution typed or typed for 
DRB4*01:01. However, all individuals included for analysis 
of the DRB3*01:01–associated haplotype were still sufficient 
typed to define the associated haplotype. Donors not typed for 
DRB4*01:01 were excluded from the statistical analysis of 
DRB4*01:01 or its associations. ‘N’ is given for each statisti-
cal analysis.
2.4 | Estimating the prevalence of HPA-1a 
alloimmunization with different DRB3*01:01–
associated haplotypes
The prevalence of alloimmunization was estimated by 
combining data from the Norwegian FNAIT screening 
study with data from the general population (control pop-
ulation in the current study). The number of HPA-1a–
negative women in the screening study who carried the 
various DRB3*01:01–associated DR-DQ haplotypes was 
estimated by applying the population frequencies of these 
haplotypes determined for the general population (con-
trol population in the current study). Patient samples of 
HPA-1a–alloimmunized women from the screening study 
were also examined for these haplotypes. The prevalence 
of HPA-1a alloimmunization was calculated as the per cent 
of HPA-1a–negative women who eventually became allo-
immunized, for each DR-DQ haplotype. Not all HPA-1a–
immunized women were included for HLA typing due to 
lack of DNA. The results from our typing of a proportion 
of immunized women were therefore adjusted to apply to 
the whole population of immunized women. Estimates are 
shown in Figure 1. Statistical analyses could not be used 
for estimated prevalence numbers. In support of the ac-
curacy of these estimates, the binomial test for measured 
frequencies of these haplotypes showed that the HPA-1a–
immunized individuals were significantly different from 
the general population.
2.5 | Genotyping of TNF-308, LTA252 and 
AGER-429 SNPs
TNF −308G>A (rs1800629), LTA 252A>G (rs909253) and 
AGER-429T>C (rs1800625) SNPs were determined with al-
lelic discrimination assays. Primers and probes are listed in 
Table S4.
2.6 | Statistics
To compare allele and haplotype frequencies between two 
groups, the chi-square test was used. Differences between 
groups were considered significant if P < .05. As the number 
of a priori hypotheses was small and related to specific hap-
lotypes, correction for multi-significance was not applied as 
recommended by Perneger TV.28
3 |  RESULTS
3.1 | The DR3-DQ2 haplotype occurs 
at a higher frequency among HPA-1a–
alloimmunized women than would be expected 
by random distribution
To identify the most common DR-DQ haplotypes in 
linkage disequilibrium with the HLA-DRB3*01:01 al-
lele, we first identified DRB3*01:01 positives among 
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F I G U R E  1  The estimated prevalence for HPA-1a alloimmunization is twice as high for women carrying DR3-DQ2 compared to DR13-
DQ6. (A) The prevalence of HPA-1a alloimmunization for groups of women with different DRB3*01:01–associated DR-DQ haplotypes in a 
prospectively selected population was examined by combining data from the Norwegian screening study 4 and DR-DQ haplotype data generated 
in the current study. (B) Each bar represents individuals enrolled in the Norwegian screening study projected to carry one or two DRB3*01:01–
associated DR-DQ haplotypes. The width of each bar represents the proportion of individuals with the indicated DR-DQ haplotype, projected from 
measured frequency of individuals carrying the different DRB3*01:01–associated DR-DQ haplotypes in the general population. The height of each 
bar represents the estimated prevalence of HPA-1a alloimmunization and is based on the actual number of HPA-1a–alloimmunized individuals 
determined to carry the specific haplotype. The overall prevalence of HPA-1a alloimmunization in DRB3*01:01–positive individuals is 36.5%.
The prevalence of immunization with DR3-DQ2 (44.5%) is about twice as high as for DR13-DQ6 (22.9%). The accuracy of these estimates is 
supported from binomial test of statistical significance for measured frequencies of these haplotypes in the HPA-1a–immunized individuals against 
the general population: Frequency of HPA-1a–alloimmunized women with DR3-DQ2 (71,8%, n = 116) against the general population (58.7%): 
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HPA-1a–immunized individuals (n  =  167) (both pro-
spectively and retrospectively selected) and in the gen-
eral population (n  =  781). The same populations were 
also typed for HLA-DQB1*02 and HLA-DRB4*01 alleles 
since these have also been reported to be associated with 
HPA-1a immunization.
As expected, in total, 94% (157) of the HPA-1a–immu-
nized women carried the DRB3*01:01 allele, compared 
to only 27.3% (213) of the general population (P <  .0001; 
Table 2); notably near similar frequency of DRB3*01:01 was 
found in the general population in other countries.29
Almost all immunized women and random donors were 
also typed by the TaqMan assay for detection of DRB3*01:01, 
and the results were in concordance with the old assay for 
typing of DRB3*01:01.
In total, 82.0% of the HPA-1a–immunized women carried 
a DQB1*02 allele, compared to only 31,0% in a random se-
lection of the general population (P < .0001) (Table 2).
Only 10.5% of HPA-1a–immunized women carried the 
DRB4*01:01 allele, not significantly different from 6.9% in a 
random selection of the general population (P = .23) (Table 2).
Next, in a detection regime to identify DRB3*01:01–as-
sociated DR-DQ haplotypes, DRB3*01:01–positive individ-
uals were further genotyped for selected alleles (as outlined 
in ‘Methods’). DRB3*01:01 is known to be associated with 
DRB1*03, DRB1*11, DRB1*12, DRB1*13 and DRB1*14 
alleles.29 However, some of the combinations are very rare 
in Caucasians.29 DR alleles known to be associated with 
DRB3*01:01 were successfully identified in 98.6% of ran-
dom donors, and all but one of the immunized women. For 
the remaining random donors and immunized woman, we 
did not have enough DNA to perform low-resolution typing 
for DRB1; the typing results were therefore uncertain.
A comparison of the DRB3*01:01–associated DR-DQ 
haplotypes (Table  3) showed that there were two dominat-
ing haplotypes, DR3-DQ2 and DR13-DQ6, together ac-
counting for > 90% of the immunized women. Furthermore, 
individuals with DR3-DQ2 were overrepresented among 
HPA-1a–immunized women (80.9%), compared to the gen-
eral population (66.7%; P < .003). In the remaining few per 
cent of immunized women, DRB3*01:01 was associated with 
less frequent haplotypes.
3.2 | DR3-DQ2 is overrepresented in 
both the retrospective and the screening groups
The HPA-1a–alloimmunized women in the study comprised 
of women identified in connection with a prospective screen-
ing study described previously 4 and women referred from the 
Allele
HPA-1a–alloimmunized 
women General population  
DRB3*01:01 94.0a (N = 167) 27.3 (N = 781) P < .0001
DQB1*02 82.0 (N = 167) 31.0 (N = 200) P < .0001
DRB4*01:01 10.5 (N = 153) 6.9 (N = 204) P = .23
Note: Number of individuals typed for the indicated allele in each population.
aPer cent of individuals in each population that typed positive for the indicated allele. 
T A B L E  2  Frequency of individuals 
carrying DRB3*01:01, DQB1*02 
and DRB4*01:01 alleles in HPA-1a–
alloimmunized women and in the general 
Norwegian population
F I G U R E  2  The frequency of the DR3-DQ2 haplotype in the general population and in HPA-1a–immunized women. Both in a population 
of HPA-1a–alloimmunized DRB3*01:01–positive women identified in a prospective screening study,4 ‘Screening population’, and in a 
population consisting of women referred from the clinic following identification of suspected FNAIT cases, ‘Retrospective population’, the per 
cent individuals carrying the DR3-DQ2 haplotype were higher than in a general population of DRB3*01:01–positive individuals (screening: 
difference12.6%, P = .016. Retrospective: difference 18.7%, P = .017). The ‘Retrospective population’ is likely enriched in women who gave 
birth to severely thrombocytopenic neonates compared to the ‘Screening population’, in which roughly a third of affected neonates were severely 
thrombocytopenic
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clinic following a pregnancy where FNAIT was diagnosed. 
Both groups showed overrepresentation of DR3-DQ2, 79.3% 
in the prospective group and 85.4% in the retrospective group 
(Figure 2), compared to 66.7% in the general population (diff 
12,6, P = .016; diff 18,7, P = .017). Population frequencies 
of DRB3*01:01–associated DR-DQ haplotypes in each of 
these groups are shown in Figure S1.
3.3 | More women become HPA-1a 
alloimmunized when DRB3*01:01 is associated 
with the DR3-DQ2 haplotype
Since the proportion of those who have the DR3-DQ2 hap-
lotype is higher in the immunized population in this study 
compared to the control population, we wanted to deter-
mine the prevalence of HPA-1a alloimmunization among 
DRB3*01:01–positive individuals having this or other 
DR-DQ haplotypes, that is the proportion of women with 
different DRB3*01:01–associated DR-DQ haplotypes who 
have become alloimmunized after one or several incompati-
ble pregnancies. In lack of a control group of non-immunized 
HPA-1a–negative women, which would have been our pre-
ferred control group, the prevalence of immunization among 
women with different haplotypes had to be estimated. For 
this estimation, we used data from the Norwegian FNAIT 
screening study, in which more than 100.000 women were 
screened for HPA-1a negativity and HPA-1a alloimmuniza-
tion in connection with pregnancy. Since DR-DQ haplotypes 
were not determined for subjects in the screening study, we 
estimated the proportion of the women carrying the differ-
ent DRB3*01:01–associated DR-DQ haplotypes by apply-
ing the frequency of each of the DRB3*01:01–associated 
DR-DQ haplotypes determined for the control population in 
the current study. The prevalence of alloimmunization was 
then calculated from the number of HPA-1a–alloimmunized 
women with a particular DRB3*01:01–associated DR-DQ 
haplotype (typed in the current study) and the estimated 
number of HPA-1a–negative women in the screening study 
who carried the same haplotype (Figure 1A). The prevalence 
of alloimmunized HPA-1a–negative, DRB3*01:01–positive, 
DR3-DQ2–positive women was 44.5%, that for DR13-DQ6 
haplotype is only 22.9% (Figure 1A,B). Hence, in HPA-1a–
negative DRB3*01:01–positive women, we estimate that 
about twice as many will become HPA-1a–alloimmunized 
during or after one or multiple HPA-1a–incompatible preg-
nancies when the DRB3*01:01 allele is associated with the 
DR3-DQ2 haplotype, compared to those with DR13-DQ6. 
The same approach was used to calculate the prevalence of 
alloimmunized HPA-1a–negative, DRB3*01:01–positive 
women: 36.5%.
3.4 | The DR7-DQ2 haplotype and 
DRB4*01:01 are overrepresented and DR15-
DQ6 is underrepresented in DRB3*01:01–
positive HPA-1a–alloimmunized women
Both haplotypes were successfully determined, by low-
resolution DRB1 typing combined with typing for specific 
alleles, in 197 of 213 (92%) individuals in the DRB3*01:01–
positive general population group and in 139 of 157 (88%) of 
HPA-1a–immunized DRB3*01:01–positive women.
Although all individuals in this study carry the DRB3*01:01 
allele on one or both chromosomes, HLA-DQB1*02 is also 
strongly associated with HPA-1a alloimmunization.13 HLA-
DQB1*02 is present in two different DR-DQ haplotypes. 
The HLA-DQB1*02:01 allele is in linkage disequilibrium 
with DRB3*01:01 in the DR3-DQ2 haplotype, while HLA-
DQB1*02:02 is present in the DR7-DQ2 haplotype, which 
segregates independent of DRB3*01:01. Furthermore, a neg-
ative association with HPA-1a alloimmunization has been 
reported for HLA-DRB1*15:01.30 This allele is present in 
DR15-DQ6, which also segregates independent of HLA-
DRB3*01:01. To determine the relative influence of these two 
DR-DQ haplotypes on HPA-1a alloimmunization, we inde-
pendently typed for DR7-DQ2 and DR15-DQ6 on the second, 
non–DRB3*01:01-associated chromosome in each individual.
The DR7-DQ2 haplotype was seen more frequently 
among the HPA-1a–immunized women (11.7%) compared to 
the general population (5.4%; P =  .03) (Figure S2A). This 
suggests that there is a weak association of the DR7-DQ2 
haplotype in DRB3*01:01–positive HPA-1a–immunized 
women. However, there were too few individuals included 
in the study to conclude upon a potential dose effect of DQ2 
on immunization. Also, DR15-DQ6 is underrepresented in 
HPA-1a–immunized women (P = .01) (Figure S2B).
To also determine whether the DRB4*01:01 allele is as-
sociated with HPA-1a alloimmunization, we examined its 
presence in DRB3*01:01–positive immunized women and 
T A B L E  3  Frequencies of the two most common DRB3*01:01–associated DR- DQ haplotypes in HPA 1a–alloimmunized women and in the 






DRB1*03:01-DQA1*05:01-DQB1*02:01 (DR3-DQ2) 80.9 (127) 66.7 (142) P < .003
DRB1*13:01-DQA1*01:03-DQB1*06:03 (DR13-DQ6) 20.4 (32) 32.9 (70) P < .008
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random blood donors. When comparing these two groups, 
the frequency of DRB4*01:01 is higher in immunized 
women, 9.2% (Table  S5), than in the random population 
(2.9%; P =  .01). DRB4*01 is known to be associated with 
DRB1*04, DRB1*07 and DRB1*09.29
All individuals carrying the DRB4*01:01 allele, both in 
the group of immunized women and in the general popula-
tion, also carried either the DR7-DQ2 (all DRB4*01:01–pos-
itive individuals except one) or the DR7-DQ3 haplotype (one 
immunized individual) (data not shown).
3.5 | An inflammation-associated single 
nucleotide polymorphism occurs at a higher 
frequency in alloimmunized compared 
to general population DR3-DQ2–positive 
individuals
Since DR3-DQ2 was found to be more associated with 
HPA-1a immunization, we wanted to examine whether this 
haplotype is associated with known factors that may increase 
the chance of immunization. Therefore, most individuals 
with a detected DR3-DQ2 haplotype were also typed for the 
Conserved Extended Haplotype (CEH) markers TNF-308A/ 
LTA252G/ AGER-429C by in-house allele discrimination as-
says (117 immunized women and 145 random donors were 
tested). Ninety per cent and 86% carried these markers, 
among immunized women and general population, respec-
tively (data not shown). In addition, we observed that 29.4% 
of the immunized women with the DR3-DQ2 haplotype in 
the retrospective group were homozygous for the TNF-308A 
marker, a more frequent occurrence compared to both the 
prospective group (10.9%; P < .025) and the control group 
(7.0%; P < .0008).
4 |  DISCUSSION
The association of HLA-DRB3*01:01 with HPA-1a alloim-
munization is well documented. In the present study, we 
show that also DR-DQ haplotype association significantly 
influences the prevalence of HPA-1a alloimmunization; 
women carrying DR3-DQ2 are estimated to be about twice 
as likely to become HPA-1a alloimmunized compared to 
those carrying DR13-DQ6, even though both of these hap-
lotypes are associated with the DRB3*01:01 allele. One 
third of HPA-1a–negative, DRB3*01:01–positive pregnant 
women with an HPA-1a–positive child were immunized; the 
estimated prevalence is, however, 44.5% if the DRB3*01:01 
allele is linked to the DR3-DQ2 haplotype.
The frequency of different HLA-DR-DQ haplotypes 
in the Norwegian population is known from typing by the 
Norwegian Bone Marrow Registry.15,17,19 We have focused 
on the most common haplotypes. The DRB3*01:01 allele 
is associated with several of these HLA-DR-DQ haplo-
types,15,29,31,32 and DR3-DQ2 and DR13-DQ6 represent the 
major two of these.29 The increased risk of alloimmuniza-
tion with DR3-DQ2 suggests that other genetic elements that 
F I G U R E  3  HLA-DR-DQ haplotype association with HPA-1a alloimmunization. (A) Alleles and SNPs that were specifically examined in 
this study in relation to HPA-1a alloimmunization. Those positively associated with HPA-1a alloimmunization are marked in green. (B) Haplotypes 
and SNPs positively associated with HPA-1a alloimmunization in HPA-1a–negative DRB3*01:01–positive women. C. Prevalence of HPA-1a 
alloimmunization in HPA-1a–negative women carrying DRB3*01:01 with DR3-DQ2 or with DR13-DQ6
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somehow increase the chance of HPA-1a alloimmunization 
are associated with this haplotype.
In addition to DRB3*01:01, the DQB1*02 alleles are 
also strongly associated with HPA-1a alloimmuniza-
tion.13,30 As shown herein, this association can largely be 
accounted for by its genetic linkage to the DR3-DQ2 haplo-
type; in the present study, 80.9% of DRB3*01:01–positive 
women carried the DR3-DQ2 haplotype. This linkage was 
even stronger (85.4%) when only retrospective cases were 
considered, which is similar to that analysed in a previ-
ous study.13 Therefore, the reported DQ2 association with 
alloimmunization may be coincidental. Alternatively, it is 
possible that DQB1*02 may represent a genetic element 
in the DR3-DQ2 haplotype that contributes to increased 
risk of alloimmunization with HPA-1a. In support of the 
latter, DQ2 is associated with alloimmunization also by a 
second allele not linked to DR3-DQ2. This second allele, 
DQB1*02:02, is present in the DR7-DQ2 haplotype,33 
which is the only other DR-DQ haplotype including DQ2 
besides DR3-DQ2.15
The DQB1*02:02 allele and, thus, the DR7-DQ2 hap-
lotype are present at a higher frequency in HPA-1a–allo-
immunized DRB3*01:01–positive women compared to in 
DRB3*01:01–positive individuals in the general population. 
Unlike the DRB3*01:01 allele, which has been functionally 
associated with alloimmunization, there is no evidence for a 
similar function associated with DQ2 alleles. Still, the pos-
sibility that such cells exist in HPA-1a–immunized women 
cannot be ruled out.
Taken together, there is still no direct evidence for a 
functional role of DQB1*02 in HPA-1a alloimmunization. 
Whether it is coincidental that both haplotypes found to be 
associated with HPA-1a immunization and FNAIT contain a 
DQB1*02 allele remains to be determined.
The DRB4*01:01 allele was also suggested by Loewenthal 
et al14 to be important for HPA-1a immunization, by acting 
in synergy with the DRB3*01:01 allele to cause more seri-
ous immunization in women positive for both these alleles.14 
The opposite was found, however, by L’abbé et al,13 where 
DRB4*01 seemed to be more frequent in random donors 
than in immunized women. Wienzek-Lischka et al,34 Delbos 
et al 35 and Sainio et al36 subsequently examined the role of 
this allele and did not find it to be overrepresented in HPA-1a–
immunized women. Wienzek-Lischka et al also found that 
the combination of DRB3*01:01 and DRB4*01:01/03 did 
not enhance immunization compared to only carrying the 
DRB3*01:01 allele alone.34 Although earlier reports14,30,34 
did not distinguish between DRB4*01:01 and DRB4*01:03, 
because there is no difference in exon 2 of these alleles and 
they phenotypically are the same, we chose to only focus 
on DRB4*01:01. We were more curious about the different 
DRB1 allele associations of DRB4*01:01 than the potential 
function of the molecule it codes for.
In this study, the DRB4*01:01 allele was relatively rare, 
but more frequent in already DRB3*01:01–positive immu-
nized women compared to the general population. For all 
women, except one, carrying this allele, it was associated 
with the DR7-DQ2 haplotype. Taken together, this points 
to a role for the DR7-DQ2 haplotype, and thereby may be 
for DQB1*02:02, rather than for the DRB4*01:01 allele, in 
HPA-1a immunization.
A major question addressed in this study is whether par-
ticular DR-DQ haplotypes are associated with increased 
prevalence of HPA-1a alloimmunization. This was deter-
mined by using prospective data from the Norwegian FNAIT 
screening study 4 and DR-DQ haplotype frequencies deter-
mined for the control population (random Norwegian blood 
donors that have the DRB3*01:01 allele) in the current 
study. The measured allele frequency of DRB3*01:01 in the 
Norwegian population in the current study was 14.3% (781 
random donors with a total of 1562 alleles, 224 positively 
typed DRB3*01:01 alleles), close to the allele frequency 
(14.9%) measured in a large European Caucasian population 
in the United States,29 lending support to the validity of our 
control population. We show that the prevalence of HPA-1a 
alloimmunization in the group of DRB3*01:01–positive 
women carrying DR3-DQ2 is twice as high as for women 
carrying the DR13-DQ6 haplotype. In support of these find-
ings, both Sainio et al36 and Wienzek-Lischka et al34 found 
that both DR3-DRB3*01:01 and DR13-DRB3*01:01 are 
overrepresented in immunized women compared to controls 
and that DR3-DRB3*01:01 is found more often than DR13-
DRB3*01:01. Both these studies are based on retrospective 
data, showing a DRB3*01:01 frequency of 100% and 98%, 
respectively. Benefiting from prospective data, however, 
we show a lower frequency of this allele. Most important, 
by comparing already DRB3*01:01–positive individuals we 
show here that DRB1*13:01 is overrepresented only by asso-
ciation with DRB3*01:01 and that the prevalence of immuni-
zation in the group of DRB3*01:01–positive women carrying 
DR13-DQ6 actually is lower than the prevalence of immuni-
zation in other DRB3*01:01–positive women.
The DR3-DQ2 haplotype has been studied for years, due to 
its association with a number of immune-mediated diseases, 
and especially autoimmune disorders.37-40 In Caucasians, the 
DR3-DQ2 haplotype is commonly a part of the conserved 
extended haplotype AH 8.1, (HLA-A1 - B8 - DRB3*01:01 - 
DRB1*03:01 - DQB1*02:01). In addition to the antigen-pre-
senting role of the separate HLA class II variants encoded 
within the haplotype, the non-MHC coding alleles embedded 
have also been studied, with C4A, TNF, LTA and AGER as 
candidate markers.39,41 There are several reports of constitu-
tively higher systemic levels of TNFα in healthy individuals 
with AH 8.1; however, evidence for direct influence of the 
8.1 AH marker (TNF-308A) on TNFα levels is ambiguous.42 
Our finding that almost all DR3-DQ2–positive women also 
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carry this 8.1 AH marker and that the frequency of homo-
zygous TNF-308A is higher in immunized women suggests 
that it may contribute to increase the likelihood of HPA-1a 
immunization.
Associations between HLA alleles and diseases have been 
known for about 50 years. DRB3*01:01 has also been shown 
to be associated with several diseases, in addition to HPA-1a 
immunization; for example, DRB3*01:01 is increased in pa-
tients with Grave's disease in Jamaicans43 and has been asso-
ciated with sarcoidosis.44 Whether the association between 
DRB3*01:01 and several different autoimmune diseases is 
coincidental because of the close linkage to other alleles in 
the AH8.1 haplotype is, however, uncertain. In addition to 
this, other HLA alleles and haplotypes have also been asso-
ciated with different diseases. One such well-known associ-
ation is the linkage between DQB1*02 and celiac disease, 
where the disease also is shown to be more frequent with a 
double dose of DQB1*02.45
In contrast to the positively associated alleles, the 
DRB1*15:01 allele has previously been reported as nega-
tively associated with FNAIT, suggesting a regulatory or sup-
pressive role of this allele.30 This negative association was 
also found in the current study, although we here suggest that 
the negative association can be accounted for by the presence 
of this allele in an underrepresented haplotype: DR15-DQ6. 
It is possible that the negative association with FNAIT could 
be due to other elements present in this haplotype and not 
necessarily the DRB1*15:01 allele itself.
As the methods for HLA typing that were applied were 
published some years ago and do not reflect the current stan-
dard of HLA typing, it cannot completely be ruled out that 
new HLA alleles could have been amplified by the primers 
used for HLA typing. Alignments of all DRB3 alleles known 
to this date, with primers in the current study for detection 
of DRB3*01:01, show that the primer pairs would also have 
amplified, among others, DRB3*02:06, *02:08, *02:21, 
*02:44, and *02:56. Common for all these alleles, how-
ever, is that they have only been found once by one lab and 
only one of them is confirmed. In addition, the prevalence 
of these alleles in different ethnic populations is not known. 
Thus, if one or two new HLA alleles had erroneously been 
amplified, it is unlikely that this would have influenced our 
main results.
The main results of this study are summarized in Figure 3. 
In summary, this study represents one of few studies in which 
MHC allele associations with HPA-1a immunization have 
taken into consideration the strong linkage disequilibrium 
that exist between specific MHC alleles. More importantly, 
and based on data from a prospective screening study, our 
results indicate that the haplotype which is associated with 
the DRB3*01:01 allele has a considerable impact on the 
chance of HPA-1a alloimmunization, likely due to yet not 
identified associated genetic elements. The haplotypes and 
alleles identified herein point to genetic elements that will 
be investigated for greater insight into the immune response 
that results in FNAIT. Potentially, these may guide a more 
accurate identification of pregnancies most at risk of FNAIT, 
in a clinical setting.
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The DR7-DQ2 Haplotype in a Native Norwegian
Population
To the Editor
Non-random association of HLA-DR and DQ alleles in
haplotypes has become important in dissecting the genetic
influence in different diseases. Recently, it was shown that
DRB1*07 and DQB1*02:01 represent the most common
DR7-DQ2 association in one defined Asian immigrant
population in Norway [1], while DRB1*07 and DQB1*02:02
are more common in European Americans [2]. The
association between these alleles in native Norwegians is
not known. Because DR7-DQ2 associations have direct
relevance to our research related to foetal and neonatal
alloimmune thrombocytopenia, we set out to address this
question.
In the Norwegian population, 24 different HLA-DR-
DQ haplotypes are considered common, with frequencies
 1% in the population [3, 4]. Spurkland et al. [3]
reported in 1992, that the DR7-DQ2 haplotype consists of
DRB1*07:01 and DQB1*02:01. Only later was the
distinction made between the DQB1*02:01 allele and a
second DQB1*02 allele, DQB1*02:02 [5] (assigned in
1994; IMGT/HLA database). Thus, because the original
paper on HLA class II haplotypes in Norwegians only
typed for polymorphisms in exon 2 [3] and the polymor-
phism distinguishing DQB1*02:01 and DQB1*02:02 lies
in exon 3, the reported DR7-DQ2 haplotype in Norway
could have included both DRB1*07:01-DQB1*02:01 and
DRB1*07:01-DQB1*02:02.
In 2003, Klitz et al. [2] reported haplotype frequencies
of the MHC class II loci DRB1, DQA1 and DQB1
(high-resolution typing) in European Americans. In this
population, the DRB1*07:01 allele was in linkage
disequilibrium with DQB1*02:02 (11.1%), DQB1*03:03
(3.7%) and DQB1*02:01 (1.1%). We therefore expected
this to be the case also in the Norwegian population, and
this was our assumption until the recent report on DR-DQ
haplotypes in Pakistani immigrants in Norway [1], where
the DRB1*07:01:01-DQB1*02:01:01 is clearly more
frequent (9.9%) than the DRB1*07:01:01-DQB1*02:02
haplotype (1.1%). The finding by Rønningen et al. [1]
prompted us to determine the nature of this association in a
native Norwegian population.
To assess the occurrence of the DRB1*07-
DQB1*02:01:01 haplotype, 202 random native Norwegian
blood donors were typed for DRB1*07, DQB1*02 and
DRB1*03 by group-specific primers [6–8]. All DQB1*02-,
DRB1*03- and/or DRB1*07-positive individuals (n = 61)
were further analysed by sequence-based typing of DQB1 for
exons 2 and 3 [9]. Haplotypes were assigned to individuals
according to the identified alleles. In 21 of the DR3- or
DR7-positive individuals, additional typing for DRB1
allowed identification of both haplotypes (data not shown),
providing confidence to the assignment. The DR and DQ
alleles in the Norwegian population are reported to have a
good fit to the Hardy–Weinberg proportion model [10].
We found that DRB1*07 was seen in combination with
DQB1*02:02 and DQB1*03:03:02, and in one individual,
in a rare combination with either DQB1*04:02:01 or -
*05:01:01 (Table 1). In contrast, DQB1*02:01:01 was
only found in combination with DRB1*03. Two donors
were positive for both DQB1*02:01:01, DQB1*02:02,
DRB1*07 and DRB1*03; which corresponds to haplotypes
DRB1*03-DQB1*02:01:01 and DRB1*07-DQB1*02:02.
Frequencies of the different haplotypes in our material are
in agreement with the haplotype frequencies given in the
sample of European Americans in 2003 [2].
In conclusion, we have determined that in a native
Norwegian population, the DR7-DQ2 haplotype consists
mainly or only of DRB1*07-DQB1*02:02, and not
DRB1*07-DQB1*02:01:01.
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Anti-human platelet antigen (HPA)-1a
antibodies may affect trophoblast functions
crucial for placental development: a
laboratory study using an in vitro model
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Anne Husebekk1, Bjørn R. Skogen1,6, Tor B. Stuge1 and Mette Kjær1,6*
Abstract
Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a bleeding disorder caused by maternal
antibodies against paternal human platelet antigens (HPAs) on fetal platelets. Antibodies against HPA-1a are
accountable for the majority of FNAIT cases. We have previously shown that high levels of maternal anti-HPA-1a
antibodies are associated with clinically significant reduced birth weight in newborn boys. Chronic inflammatory
placental lesions are associated with increased risk of reduced birth weight and have previously been reported in
connection with FNAIT pregnancies. The HPA-1a epitope is located on integrin β3 that is associated with integrin
αIIb (the fibrinogen receptor) on platelets and megakaryocytes. Integrin β3 is also associated with integrin αV
forming the αVβ3 integrin heterodimer, the vitronectin receptor, which is expressed on various cell types, including
trophoblast cells. It is therefore thinkable that maternal anti-HPA-1a antibodies present during early pregnancy may
affect placenta function through binding to the HPA-1a antigen epitope on invasive throphoblasts. The aim of the
study was to examine whether interaction of a human anti-HPA-1a monoclonal antibody (mAb) with HPA-1a on
trophoblast cells affect adhesion, migration and invasion of extravillous trophoblast cells.
Methods: An in vitro model with human anti-HPA-1a mAb, clone 26.4, and the first trimester extravillous trophoblast
cell line HTR8/SVneo was employed. The xCELLigence system was utilized to assess the possible effect of anti-HPA-1a
mAb on adhesion and migration of HTR8/SVneo cells. Specially designed chambers precoated with Matrigel were used
to assess the effect on the invasive capacity of cells.
Results: We found that human anti-HPA-1a mAb 26.4 partially inhibits adhesion and migratory capacity of
HTR8/SVneo cells.
Conclusions: Our findings suggest that anti-HPA-1a antibodies may affect trophoblast functions crucial for
normal placental development. Future studies including primary throphoblast cells and polyclonal anti-HPA-1a
antibodies are needed to confirm these results.
Keywords: Alloimmunization, HPA-1a, Anti-HPA-1a antibodies, Trophoblast cells, Placental development, αVβ3,
Vitronectin receptor, Fetal and neonatal alloimmune thrombocytopenia
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Background
Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
is caused by maternal antibodies against alloantigens
on fetal platelets. It is a rare, but potentially life threat-
ening disorder with intracranial hemorrhage (ICH) as
the most severe complication. Severe gastrointestinal
and pulmonary hemorrhages have also been reported [1].
Antibodies against human platelet antigen (HPA)-1a
are accountable for nearly 85% of FNAIT cases [2]. The
frequency of FNAIT due to anti-HPA-1a antibodies is
around one per 1100 live births [2, 3]. We have previ-
ously found that high levels of maternal anti-HPA-1a
antibodies are associated with clinically significant re-
duced birth weight in newborn boys [4]. A similar ob-
servation was made in an international multicenter
study of FNAIT-associated ICH, showing that 23% of
neonates with ICH were small for gestational age [5].
Chronic inflammatory placental lesions like chronic vil-
litis and intervillositis have been reported in association
with FNAIT cases [6] and such placental lesions are
known to be associated with increased risk of fetal
growth restriction.
Integrin β3, carrying the HPA-1 antigen epitope, is
expressed on platelets and megakaryocytes as part of
αIIbβ3 integrin heterodimer, the fibrinogen receptor.
Integrin β3 is also associated with αV integrin forming
integrin heterodimer αVβ3, also known as vitronectin
receptor. The vitronectin receptor is expressed on vari-
ous cell types, including trophoblast cells [7–9].
During early pregnancy, a population of trophoblast
cells differentiates into highly invasive extravillous tro-
phoblasts (EVT). EVT invade the decidualized endomet-
rium reaching the inner third of the myometrium, and
migrate along the spiral arteries remodeling them into
large diameter low resistance vessels [10]. EVT migration
and invasion into the uterus continues until mid-gestation
and is regulated by various factors of both maternal and
embryonic origin [11]. Impaired trophoblast invasion and
insufficient remodeling of placental spiral arteries are
common histopathological findings in placentas from
pregnancies complicated by preeclampsia and low birth
weight [12, 13].
During migration and invasion, EVT cells undergo in-
tegrin switch and upregulate expression of adhesion
molecules on cell surface, including the αVβ3 [8, 14].
The important role of αVβ3 in mediating migration and
invasion of primary cytotrophoblasts (CTB) was demon-
strated in vitro [8, 15]. It has therefore been speculated
that anti-HPA-1a antibodies may affect placental devel-
opment [4]. Anti-HPA-1a antibodies can bind HPA-1a
on αVβ3 expressed on trophoblast cells [9, 16], and we
hypothesize that this binding may affect EVT invasion,
spiral artery remodeling, and in turn lead to reduced
placental function.
The objective of this study was to test whether anti-
HPA-1a antibodies affect adhesion, migration and inva-
sive capacity of EVT cells. For functional experiments
we used an experimental in vitro model with human re-
combinant anti-HPA-1a monoclonal antibody (mAb),
clone 26.4 [16], and a first trimester human EVT-derived
cell line, HTR8/SVneo [17].
Methods
Cell culture
Human first trimester extravillous trophoblast-derived
cell line, HTR8/SVneo, was kindly provided by Charles
Graham (Department of Anatomy and Cell Biology at
Queen’s University, Kingston, ON, Canada). The cell line
was generated by immortalization of primary villous
explant culture from first trimester human placenta
(8–10 WG) with SV40 virus [17]. HTR8/SVneo is a
hypotriploid cell line (3n-) [18]. Cells were cultured in
RPMI-1640 (Sigma-Aldrich, St. Louis, MO), supple-
mented with 10% FBS (Lonza, Basel, Switzerland), 100
U/ml penicillin, 100 U/ml streptomycin (Lonza) and
maintained at 37 °C, in a 5% CO2 humidified atmos-
phere. The cells were grown to 70–80% confluency
and passaged 24 h prior to experiments. The cells
were detached by incubation with 2 mM EDTA in PBS
for 5 min at 37 °C.
Antibodies
A recently developed human recombinant anti-HPA-1a
IgG1 mAb (clone 26.4) [16] was used to explore the ef-
fect on invasive trophoblast cells. Murine anti-human
αVβ3 mAb, clone LM609 (Millipore, Billerica, MA) was
used as positive control for cell functional studies. So-
dium azide from LM609 sample was removed by buffer
exchange with PBS using PD SpinTrap G-25 (GE
Healthcare, Little Chalfont, UK). Integrin β3 was detected
using murine mAb, clone SZ21, HPA-1-reactive [19] (Dako,
Glostrup, Denmark) and rabbit mAb, clone EPR2417Y
(Abcam, Cambridge, UK). Alexa Fluor 488-conjugated goat
anti-mouse and goat anti-human antibodies (Invitrogen,
Carlsbad, CA) were used as secondary antibodies in flow
cytometry experiments. Human myeloma plasma IgG1
(Sigma) and murine IgG1 (Beckman Coulter, Brea, CA)
were used as isotype controls. Horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (Thermo Scientific,
Waltham, MA) was used as a detection antibody in the
western blot experiment.
Western blot
Platelets from an HPA-1aa-genotyped donor (16 × 108
cells) and HTR8/SVneo cells (20 × 106 cells) were lysed
using 3 ml RIPA buffer (Sigma) in the presence of prote-
ase inhibitor (cOmplete Tablets Mini EDTA-free, Roche
Diagnostics, Basel, Switzerland). Twelve microliters of
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platelet lysate diluted 1:1000 and 12 μl of HTR8/SVneo
cell lysate were reduced and separated in a 4–12% SDS
polyacrylamide gel (Life Technologies, Carlsbad, CA).
Electrophoresed samples were transferred to a PVDF
membrane (Life Technologies). Nonspecific binding sites
were blocked by Super blocking buffer (Thermo Scien-
tific) containing 0.05% Tween 20 and 0.2% goat IgG
(Thermo Scientific) for 1 h. Primary and secondary anti-
bodies were diluted in Super blocking buffer containing
0,05% Tween 20. The PVDF membrane was incubated
overnight at 4 °C with rabbit anti-β3 antibody diluted
1:2000 (clone EPR2417Y). After a washing step, the
membrane was incubated with HRP-conjugated goat
anti-rabbit IgG diluted 1:1000 for 1 h at RT followed by
a washing step with PBS 0.05% Tween 20. The mem-
brane was covered by 3 ml of Supersignal West Femto
Maximum Sensitivity Substrate (Thermo Scientific) and
left for 5 min in the dark at RT. Integrin β3 was visualized
using the luminescent image analyzer ImageQuant LAS
4000 (GE Healthcare, Little Chalfont, UK). Integrin αVβ3
purified from human placenta was used as a positive con-
trol (Millipore, Billerica, MA). The expected β3 subunit
band is of approximately 90–110 kDa.
Flow cytometry
To stain cell surface membrane integrins, the HTR8/
SVneo cells were harvested, washed and re-suspended in
PBS 0.2% bovine serum albumin, and incubated 10 min
at RT with unconjugated mouse anti-human β3 (clone
SZ21) or human anti-HPA-1a (clone 26.4) mAbs. Mouse
and human IgG1 were used as isotype controls. After
a washing step, cells were stained with Alexa Fluor
488-conjugated goat anti-mouse and goat anti-human
antibodies respectively, and analyzed by flow cytometry
(Canto, Becton Dickinson, Franklin Lakes, NJ). The ac-
quired data was analyzed using FlowJo software (TreeStar,
Ashland, OR, USA).
HPA-1 genotyping
The DNA and RNA from HTR8/SVneo cells and donor
samples were isolated and used for HPA-1 genotyping
by TaqMan 5′ nuclease assay as described previously
[20, 21].
Y-chromosome DNA test
The DNA isolated from HTR8/SVneo cells was used for
Y-chromosome DNA test by TaqMan 5′ nuclease assay.
The primers used for the assay were described previ-
ously [22] and FAM-labelled probe was designed in
house.
Monitoring cell adhesion and migration
Cell adhesion and migration were monitored in real time
using the xCELLigence system (Roche Applied Science,
Penzberg, Germany) [23]. For determining the rate of
cell adherence, E-plate 16 assemblies were coated with
human vitronectin (Promega, Madison, WI) by incubat-
ing 1 μg/ml solution in 100 μl volume for 1 h at 37 °C.
The wells were washed twice with PBS before 50 μl
complete medium was added and the background mea-
surements recorded. The cells were seeded at 20,000
cells/well in a 40 μl volume. From a solution of 200 μg
antibodies/ml PBS, 10 μl were added to each well (hu-
man IgG1 as negative control, 26.4 and LM609). Each
plate was then assembled on the RTCA DP analyzer, and
data were gathered at 5-min intervals for 7 h at 37 °C, in
a 5% CO2 humidified atmosphere.
Cell migration was monitored using specially designed
CIM-plate 16 with 8-μm pores. The sensor side (bottom
side) of each well of the upper chamber was coated with
human vitronectin by incubating 30 μl of the 1 μg/ml
solution for 30 min at RT. The lower chambers were
filled with medium containing 10% FBS, used as chemo-
attractant. The upper chambers were filled with serum-
free medium (50 μl/well), and the plate was incubated at
37 °C in 5% CO2 for 1 h. After recording background
measurements, the cells were seeded into the upper
chamber at 40,000 cells in 40 μl per well and 10 μl of
200 μg/ml antibodies in PBS were added. The plate was
then incubated for 30 min at RT, assembled on the
RTCA DP analyzer and data collected every 15 min for
24 h at 37 °C, in a 5% CO2 humidified atmosphere. The
obtained data were analyzed using the RTCA 1.2 soft-
ware supplied with the instrument.
Invasion assay
Cell invasion was evaluated using BD BioCoat Matrigel
Invasion Chambers (BD Biosciences). The Chambers (24
well Plate 8 Micron with Control inserts) were prepared
following the manufacturer’s instructions. The RPMI
1640 medium with 5% FBS was used as chemoattractant.
HTR8/SVneo cells were seeded into each insert at
40,000 cells/well in a 180 μl volume in serum free
medium and 20 μl of 200 μg/ml antibodies in PBS were
added (total antibody concentration of 20 μg/ml). The
plate was incubated for 48 h at 37 °C, in a 5% CO2 hu-
midified atmosphere. After incubation, the non-invading
cells were scrubbed from the upper part of the inserts by
a cotton swab.
The invaded cells were measured by the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide)
assay. The MTT (Sigma) at 5 mg/ml in RPMI 1640
medium without phenol red, was diluted 1:10 and 350 μl
of the dilution was added to each clean well. The inserts
were transferred to MTT solution and incubated for 2 h
at 37 °C, in a 5% CO2 humidified atmosphere. Next, the
inserts were transferred into clean wells with 220 μl of
0.04 M HCl in pure isopropanol and incubated for 5 min
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at RT. The inserts were removed and the solution trans-
ferred to centrifuge tubes and centrifuged for 2 min at
16,000 x g. Of the solution, 100 μl was transferred into a
96-well microtiter plate and absorption at 560 nm was
measured by an ELISA- reader (Multiskan Ex, Thermo
Scientific).
Statistical Analysis
A one-way analysis of variance (ANOVA) in SPSS soft-
ware (SPSS Inc., Chicago, IL, USA) was used to analyze
adhesion, migration and invasion experimental data. A
P-value of < 0.05 was considered significant. Sigma Plot
13 software (San Jose, CA) was used to present the data.
Results
A human anti-HPA-1a mAb 26.4 binds HPA-1a epitope on
HTR8/SVneo cells
Integrin β3 expression by HTR8/SVneo cells was
assessed with Western blot and flow cytometry tech-
niques. Both techniques demonstrated expression of integ-
rin β3 by HTR8/SVneo cells (Fig. 1a and b). The cells
expressed αV, but were negative for αIIb (data not shown),
indicating that HTR8/SVneo cells express β3 integrin only
in association with αV integrin. Next, HTR8/SVneo cells
were genotyped HPA-1ab. Finally, flow cytometry analysis
demonstrated that human anti-HPA-1a mAb bound to in-
tact HTR8/SVneo cells (Fig. 1a).
A human anti-HPA-1a mAb 26.4 partially inhibits adhesion
and migratory capacity of HTR8/SVneo cells
The effect of a mAb 26.4 on trophoblast cell adhesion
and migration was explored using the xCELLigence sys-
tem. mAb 26.4 was used at a concentration of 20 μg/ml,
which corresponds to about 400 IU/ml of anti-HPA-1a
antibody activity as measured by quantitative mAb
immobilization of platelet antigens (MAIPA) assay [24].
mAb 26.4 significantly inhibited adhesion and migration
of HTR8/SVneo cells to vitronectin-coated membranes
by 15–20% (Fig. 2a and b) and 18–23% (Fig. 2c and d),
respectively. Anti-αVβ3 murine mAb (clone LM609)
similarly inhibited adhesion and migration of HTR8/
SVneo cells (data not shown).
The effect of mAb 26.4 on invasive capacity of first tri-
mester trophoblast cells was studied utilizing Matrigel
pre-coated invasion chambers. The mAb inhibited inva-
sive capacity of cells in three out of four independent ex-
periments by 9, 15 and 25% (Fig. 3). The inhibition was
not statistically significant (p = 0.13). Anti-αVβ3 murine
mAb (clone LM609) did not affect invasive capacity of
HTR8/SVneo cells (data not shown).
HTR8/SVneo cells originate from a female conceptus
To identify whether HTR8/SVneo cells originate from a
female or male conceptus, the Y-chromosome DNA test
has been performed. HTR8/SVneo cells were tested
negative for Y-chromosome DNA, indicating that the
cells originate from a female conceptus.
Discussion
In the present study, we have demonstrated that a human
HPA-1a-specific mAb inhibit adhesion and migratory cap-
acity of EVT cells in an in vitro model.
To study the possible effect of anti-HPA-1a antibodies
on EVT we utilized transformed first trimester EVT-
derived cells (HTR8/SVneo cell line), which were re-
ported to share phenotypic and functional characteristics
of EVT cells [17, 25]. We have shown that HTR8/SVneo
cells express HPA-1a epitope as part of αVβ3 integrin
complex, and importantly, that anti-HPA-1a antibodies
interact with HPA-1a on these cells. In this study, we
used a human anti-HPA-1a mAb, clone26.4, generated
from a B cell derived from a woman HPA-1a immunized
in connection with pregnancy, who had two children af-
fected by FNAIT. mAb 26.4 was expressed recombi-
nantly and found to be highly specific for HPA-1a,
bound strongly to HPA-1a epitopes on αIIbβ3 from
platelets as well as αVβ3 from trophoblasts [16]. Thus,
the HTR8/SVneo cell line with mAb 26.4 could be a


























Fig. 1 Expression of integrin β3 and HPA-1a on HTR8/SVneo cells.
a Flow cytometric analysis of cells incubated with murine anti-human
β3 HPA-1-reactive mAb SZ21 and human HPA-1a-specific mAb 26.4, or
isotype control. b Detection of integrin β3 in lysed HTR8/SVneo cells
by Western blot. Integrin αVβ3 isolated from human placenta used as
control. Integrin β3 detected as a band of about 100 kDa in the control
and cell lysate. Western blot image was spliced to rearrange the order
of samples within one experiment. Dashed lines indicate where the
images were joined. Figure A and B are representative for at least
three independent experiments
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useful model to study possible effect of anti-HPA-1a
antibodies on EVT.
The idea that alloantibodies reactive with fetal integ-
rins expressed on trophoblast cells can impair placental
function is not new. A histological study of placentas
from FNAIT-affected pregnancies described chronic vil-
litis in pregnancies not treated with IVIG [26]. And in a
recent histopatological study, FNAIT was associated
with chronic chorioamnionitis, basal chronic villitis and
intervillositis [6]. In addition, a case of FNAIT associated
with massive chronic intervillositis has also been de-
scribed [27]. Chronic villitis and intervillositis are pla-
cental lesions known to be associated with poor fetal
growth [28, 29]. Further, an association between FNAIT
due to anti-HPA-1a antibodies and increased risk of
miscarriage has also been suggested, indicating that
placental development may be affected in early stages
of pregnancy [30, 31].
Vitronectin receptor, carrying HPA-1 antigen epitope,
is crucial for cell-matrix and cell-cell interactions, modu-
lating growth, survival, motility and differentiation of an-
giogenic endothelial cells (EC), osteoclasts, tumor cells
and other cell types [32]. Blocking αVβ3 was shown to


































































Fig. 2 Effect of anti-HPA-1a antibodies on EVT adhesion and migration. HTR8/SVneo cells were plated on E-plate 16 (for adhesion experiments)
and CIM-plate 16 (for migration experiments) in the presence of mAb 26.4 or human IgG1 as a negative control. Cell adhesion was monitored
using xCELLigence system over 7 h, and cell migration over 24 h. The samples were run in triplicates and experiments repeated three times each.
Each column represent the range in cell index of one sample run in triplicate. Results presented in the graphs (distinguished by experiment due
to high variations in cell index between the experiments) are from three independent experiments: a adhesion; c migration. Plots visualize cell



















Fig. 3 Effect of anti-HPA-1a antibodies on invasive capacity of EVT.
HTR8/SVneo cells were cultured in Matrigel coated chambers in the
presence of mAb 26.4 or human IgG1 as a negative control for 48 h.
The samples were run in quadruplicates and experiment repeated
four times. Each column represent the range in cell index of one
sample run in quadruplicate. Cell invasion was evaluated by
MTT-assay. The invasion data is expressed as the ratio of invasion
through the Matrigel Matrix and membrane relative to the migration
through the control membrane
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EC, and suppress angiogenesis [33–35] impede tumor
progression [36], and hinder osteoclast adhesion and mi-
gration [32]. The important role of αVβ3 in mediating
EVT cells invasion [8] and adhesion to ECs [37, 38] was
shown in vitro.
Further, the capacity of anti-HPA-1a antibodies to
affect αVβ3-expressing EC in vitro has been reported
[35, 39, 40]. Anti-HPA-1a maternal sera affected spread-
ing and monolayer integrity of human umbilical cord
endothelial cells (HUVEC) [39] and inhibited HUVEC
proliferation and formation of capillary-like networks
[35]. The latter findings suggest that anti-HPA-1a anti-
bodies can cause systemic vascular damage, impair
angiogenesis, and subsequently can be an independent
cause of FNAIT-associated ICH. Further, in a recent
study, Santoso S. with co-workers have shown that only
anti-HPA-1a antibodies binding selectively to the αVβ3
complex interfere with angiogenesis [40].
Mechanisms of inhibitory effects of anti-HPA-1a anti-
bodies are still incompletely understood. It has been
shown that anti-HPA-1a antibodies can impair angiogenic
and increase proapoptotic signaling in HUVECs [35]. It
has also been hypothesized that anti-HPA-1a IgG anti-
bodies block the ligand RGD binding site on αVβ3 and
αIIbβ3 by indirect competition (i.e., steric hindrance) [41].
The HPA-1a epitope is formed by only one amino acid
change, L33P, in integrin β3, and, therefore, all anti-
HPA-1a antibody epitopes overlap reacting with the L33
residue. Yet, anti-HPA-1a antibodies are reported to be
heterogeneous in their footprint on integrin β3 [42] and
binding affinity [43–45]. In fact, recently it was found
that antibodies of this specificity can be even more com-
plex; αVβ3-, αIIbβ3-specific, or bind antigen independently
of the complex [40]. Thus, the effect of a single mAb spe-
cific for HPA-1a, as used in this study, may not be repre-
sentative for different polyclonal antibody profiles among
immunized women. Still, our finding that an anti-HPA-1a
mAb could affect functions of HTR8/SVneo cells is inter-
esting, indicating that anti-HPA-1a antibodies may affect
functions of extravillous trophoblast cells in vivo.
Only male neonates had significantly reduced birth
weight in pregnancies with high levels of maternal anti-
HPA-1a antibodies in a retrospective observational study
[4]. Male sex of the fetus is a well known risk factor for
adverse pregnancy outcome [46]. Evidence is emerging
on the influence of fetal sex on placental development
and function [47]. The placenta displays sexually dis-
morphic differences in gene expression and responds to
maternal factors in a sex-dependent manner [48]. The
magnitude of the effects of anti-HPA-1a antibodies on
trophoblast cells may depend on the sex of the placenta.
In this study we used a cell line HTR8/SVneo which we
found to originate from a female placenta. In the follow
up studies, it is therefore important to compare the
effects of anti-HPA-1a antibodies on trophoblast cells
originating from male and female placentas.
Conclusions
We have demonstrated that a human anti-HPA-1a mAb
impaired adhesion and migratory capacity of EVT-
derived cell line in vitro. We speculate that anti-HPA-1a
antibodies may hinder placental development, and con-
sequently, may be involved in early pregnancy loss as
well as poor placental function. Further studies with pri-
mary trophoblast cells and maternal anti-HPA-1a sera,
together with a histopathological study of placentas from
pregnancies affected by FNAIT are important to support
our finding.
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